


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:47:44Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405453" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405453</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>scirep</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405453</article-id><article-id pub-id-type="pmcid-ver">PMC12405453.1</article-id><article-id pub-id-type="pmcaid">12405453</article-id><article-id pub-id-type="pmcaiid">12405453</article-id><article-id pub-id-type="pmid">40897743</article-id><article-id pub-id-type="doi">10.1038/s41598-025-15089-3</article-id><article-id pub-id-type="publisher-id">15089</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Deep learning model for screening causes of activated partial thromboplastin time prolongation using clot waveform analysis at multiple wavelengths</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Matsuda</surname><given-names initials="M">Masato</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shimomura</surname><given-names initials="D">Daiki</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Suzuki</surname><given-names initials="T">Takeshi</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tabuchi</surname><given-names initials="Y">Yuka</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kurono</surname><given-names initials="H">Hiroshi</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nishi</surname><given-names initials="K">Keisuke</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Arai</surname><given-names initials="N">Nobuo</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hoshiyama</surname><given-names initials="Y">Yoshiki</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kamioka</surname><given-names initials="M">Mikio</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Moriyama</surname><given-names initials="M">Masato</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Matsumoto</surname><given-names initials="T">Tomoko</given-names></name><address><email>t.matsumoto@sta.tenri-u.ac.jp</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03b0x6j22</institution-id><institution-id institution-id-type="GRID">grid.412181.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 0639 8670</institution-id><institution>Medical Laboratory Division, </institution><institution>Niigata University Medical and Dental Hospital, </institution></institution-wrap>1-754, Asahimachi-dori, Chuo-ku, Niigata, 951-8520 Japan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05g2axc67</institution-id><institution-id institution-id-type="GRID">grid.416952.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 4277</institution-id><institution>Department of Laboratory Medicine, </institution><institution>Tenri Hospital, </institution></institution-wrap>200, Mishima-cho, Tenri, 632-8552 Nara Japan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00gfstq19</institution-id><institution-id institution-id-type="GRID">grid.419812.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1777 4627</institution-id><institution>Sysmex Corporation, </institution></institution-wrap>4-4-4, Takatsukadai, Nishi-ku, Kobe, 651-2271 Hyogo Japan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04ww21r56</institution-id><institution-id institution-id-type="GRID">grid.260975.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 0671 5144</institution-id><institution>Department of Medical Oncology, </institution><institution>Niigata University Graduate School of Medical and Dental Sciences, </institution></institution-wrap>1-757, Asahimachi-dori, Chuo-ku, Niigata, 951-8510 Japan </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00d440w27</institution-id><institution-id institution-id-type="GRID">grid.442871.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0721 427X</institution-id><institution>Department of Clinical Laboratory, </institution><institution>Tenri University, </institution></institution-wrap>80-1, Bessho-cho, Tenri, 632-0018 Nara Japan </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/012eh0r35</institution-id><institution-id institution-id-type="GRID">grid.411582.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 1017 9540</institution-id><institution>Present Address: Department of Clinical Laboratory Sciences, School of Health Sciences, </institution><institution>Fukushima Medical University, </institution></institution-wrap>10-6, Sakae-machi, Fukushima, 960-8516 Japan </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">478255</issue-id><elocation-id>32336</elocation-id><history><date date-type="received"><day>10</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>5</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="41598_2025_Article_15089.pdf"/><abstract id="Abs1"><p id="Par1">Activated partial thromboplastin time (APTT) prolongation occurs due to coagulation factor deficiencies/inhibitors, lupus anticoagulant (LA), and anticoagulant-taking, necessitating discrimination through further testing. Clot waveform analysis (CWA) can discriminate causes while measuring APTT, but conventional CWA exhibits moderate accuracy due to visual judgement and limited parameter use. We applied deep learning (DL) techniques to huge numerical data constituting clot waveforms and their first- and second-derivative curves (CWA curves) to leverage hidden features for developing an accurate classification model. We utilized a multi-wavelength detection system embedded in modern coagulometers to obtain multi-wavelength CWA curves. A convolutional neural network-based DL model was trained on 683 samples (135 hemophilic, 95 LA-positive, 99 heparin-treated, 105 warfarin-treated, and 249 direct oral anticoagulant-treated) and evaluated using 10-fold cross-validation. Conventional CWA parameters showed limited discrimination abilities (area under the curve [AUC] 0.532&#8211;0.858). DL models using single-wavelength CWA curves achieved higher performance (AUC 0.943&#8211;0.988), and multi-wavelength CWA curves further improved it (AUC 0.961&#8211;0.993) with high sensitivity (&#8805;&#8201;88.0%), specificity (&gt;&#8201;92.0%), and overall accuracy (88.4%), although the performance may depend on reagents and/or analyzers. DL models using multi-wavelength CWA curves show promise as high-performance screening tools for classifying APTT prolongation causes and are best built in each laboratory.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Activated partial thromboplastin time</kwd><kwd>Anticoagulants</kwd><kwd>Clot waveform analysis</kwd><kwd>Deep learning</kwd><kwd>Hemophilia</kwd><kwd>Lupus anticoagulant</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Haematological diseases</kwd><kwd>Laboratory techniques and procedures</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par3">Identifying the cause(s) of prolonged activated partial thromboplastin time (APTT) is crucial for assessing bleeding and thrombotic risks; however, commonly used approaches often involve multiple time-consuming tests and present technical and practical concerns regarding their discriminative performance in clinical settings. The main causes associated with bleeding risk are coagulation factor deficiencies, typically factor VIII (FVIII) and IX (FIX) (i.e., hemophilia A (HA) and hemophilia B (HB))<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>. Specific coagulation factor inhibitors, typically against FVIII (i.e., acquired hemophilia A (AHA)), also cause prolonged APTT and severe bleeding, which are sometimes life-threatening<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. In contrast, the major cause of thrombotic risk is lupus anticoagulant (LA)<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref></sup>. In addition, the use of anticoagulants, typically unfractionated heparin (UFH), is a well-known cause of APTT prolongation in routine laboratory testing<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. Other anticoagulants, such as warfarin (i.e., vitamin K antagonist, VKA) and direct oral anticoagulants (DOACs) can also cause APTT prolongation, although their effects vary depending on the reagent used and are often more pronounced in other clotting time assays, such as the prothrombin time (PT)<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>.</p><p id="Par4">APTT prolongation may be accompanied by clinical symptoms (e.g., bleeding or thrombosis tendency) in many cases. However, asymptomatic or unexpected APTT prolongation is also frequently observed in hemostasis laboratories, most typically due to LA-positive detected during preoperative screening or heparin contamination from blood samples drawn through central venous catheters<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref></sup>. Hence, identification of the causes of APTT prolongation is pivotal in clinical settings.</p><p id="Par5">The mixing test is the first-line routine tool for investigating the causes of APTT prolongation<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref></sup>; however, it has several shortcomings. After ruling out the effects of anticoagulants (e.g., UFH, VKA, and DOACs) by checking medical records and performing assays (e.g., anti-Xa assays and PT tests), a mixing test is performed to examine whether the APTT prolongation is corrected by the addition of normal plasma to the test sample. Correction generally indicates coagulation factor deficiency, whereas non-correction indicates the presence of inhibitor(s) (e.g., LA or anti-FVIII inhibitors)<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. The results of correction/non-correction guide follow-up tests (e.g., coagulation factor assays or LA tests)<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. The mixing test is simple and useful, but the results can be altered by several factors, such as the normal plasma used<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> and numerical indexes used to assess the results<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Furthermore, this strategy is costly and time-consuming<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>, necessitating effective, inexpensive, and time-saving methods.</p><p id="Par6">Clot waveform analysis (CWA) is a potentially promising tool for expeditiously screening APTT prolongation causes, while measuring APTT, guiding further confirmatory testing. CWA is a technique for analyzing curves generated by continuously measuring changes in light transmittance or absorbance during fibrin formation in clotting time assays, typically performed in APTT tests<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>. The first- and second-derivatives of the curve reflect the coagulation velocity and acceleration, respectively. The maximum coagulation velocity (|min1|), maximum coagulation acceleration (|min2|), and maximum coagulation deceleration (max2) are well-known quantitative CWA parameters for diagnosing and evaluating coagulation disorders and monitoring anticoagulant therapy<sup><xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR15">15</xref></sup>. Furthermore, first- and second-derivative curves provide visually identifiable qualitative information by representing their unique shapes, such as biphasic and shoulder curves, depending on coagulation abnormalities<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR17">17</xref></sup>. Considering the features of CWA, this technique may be useful for identifying the causes of APTT prolongation, particularly in cases with unexpected and/or isolated APTT prolongation, which can overcome the shortcomings of the mixing test. However, visual inspection is subjective, and visual features can overlap among coagulation abnormalities. A flowchart developed to identify the causes of APTT prolongation using several quantitative CWA parameters has shown approximately 75% accuracy<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>, which is somewhat short of the requirements for clinical use. The effective utilization of the CWA technique still needs exploring.</p><p id="Par7">In this study, we aimed to develop a classification model of APTT prolongation causes by applying deep learning (DL) to CWA curves obtained using a multi-wavelength detection system. CWA curves refer to three curves: clot waveform and its first- and second-derivative curves. The CWA curves were firstly modified using a recently developed technique, adjustment method<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>, in which maximum and minimum transmittance were defined as 100% and 0%, respectively (i.e., not used in absolute values). This technique is reportedly useful for understanding the features of CWA curves, such in hemophilia and DOAC-treated samples<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup>. Introduction of DL techniques is expected to help the utilization of fruitful data hidden in the CWA curves, namely, the huge amount of numerical raw data composing the curves. Such techniques can be advantageous in terms of utilizing small features in the curves that cannot be identified visually and do not limit the use of the curves to several quantitative parameters. The multi-wavelength detection system (i.e., simultaneous measurements of light transmittance at multiple wavelengths such as 405, 575, 660, and 800&#160;nm) embedded in modern automated coagulation analyzers was used for the first time in the context of performing CWA and obtaining the curves for screening APTT prolongation causes. CWA is usually performed using single-wavelength at around 660&#160;nm because the wavelength is used in clot-based assays, and the other wavelengths are used for checking interfering substances (i.e., so-called HIL detection) and chromogenic assays<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. This method can obtain unique features in CWA curves depending on wavelengths and APTT abnormalities.</p><p id="Par8">Taking advantage of the three techniques&#8212;adjustment method, DL, and multi-wavelength measurement&#8212;, CWA curves obtained from more than 680 samples with APTT prolongation due to hemophilia (HA, HB, and AHA), LA, UFH, VKA, and DOACs were trained through a convolutional neural network (CNN)-based DL technique to develop the classification model. The reason for developing a model that classifies the APTT prolongation causes into just five categories (i.e., hemophilia, LA, UFH, VKA, and DOACs) was to distinguish between bleeding and thrombotic risks, while also differentiating anticoagulant effects, which are major reasons frequently encountered in clinical settings<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref></sup>. The developed model was validated for its discriminative performance, compared to using conventional indices (i.e., APTT values and CWA parameters) as baselines, since, to our knowledge, this is the first study to apply DL techniques to the screening of APTT prolongation causes. Its clinical utility was also assessed.</p></sec><sec id="Sec2"><title>Results</title><sec id="Sec3"><title>Sample profiles</title><p id="Par9">We included 683 citrated plasma samples with APTT prolongation and either a hemophilia diagnosis, LA diagnosis, or anticoagulant therapy using UFH, VKA, or DOACs; 647 samples were obtained after routine coagulation tests at Niigata University Medical and Dental Hospital and Tenri Hospital in Japan, and the others were hemophiliac-derived commercial samples that differed in their lot numbers obtained from George King Bio-Medical Inc. in the USA. The hemophilia group consisted of HA, HB, and AHA samples. The DOACs group was composed of samples obtained from patients treated with dabigatran (Dab), rivaroxaban (Riv), apixaban (Api), or edoxaban (Edo).</p><p id="Par10">The detailed profiles of each group were as follows:<list list-type="order"><list-item><p id="Par11">Hemophilia group (<italic toggle="yes">n</italic>&#8201;=&#8201;135):<list list-type="bullet"><list-item><label/><p id="Par13">HA samples (<italic toggle="yes">n</italic>&#8201;=&#8201;64).<list list-type="bullet"><list-item><label/><p id="Par14">APTT: median&#8201;=&#8201;56.3&#160;s; interquartile range (IQR)&#8201;=&#8201;45.7&#8211;97.2&#160;s; range&#8201;=&#8201;35.7&#8211;159.8&#160;s.</p></list-item><list-item><label/><p id="Par15">FVIII activity (FVIII:C): median&#8201;=&#8201;6.5 IU/dL; IQR&#8201;=&#8201;&lt;&#8201;1.0&#8211;15.6 IU/dL; range&#8201;=&#8201;&lt;&#8201;1.0&#8211;43.1 IU/dL.</p></list-item></list></p></list-item><list-item><label/><p id="Par16">HB samples (<italic toggle="yes">n</italic>&#8201;=&#8201;18).<list list-type="bullet"><list-item><label/><p id="Par17">APTT: median&#8201;=&#8201;106.3&#160;s; IQR&#8201;=&#8201;51.7&#8211;123.1&#160;s; range&#8201;=&#8201;35.8&#8211;141.8&#160;s.</p></list-item><list-item><label/><p id="Par18">FIX activity (FIX:C): median&#8201;=&#8201;&lt;&#8201;1.0 IU/dL; IQR&#8201;=&#8201;&lt;&#8201;1.0&#8211;2.0 IU/dL; range&#8201;=&#8201;&lt;&#8201;1.0&#8211;12.0 IU/dL.</p></list-item></list></p></list-item><list-item><label/><p id="Par19">AHA samples (<italic toggle="yes">n</italic>&#8201;=&#8201;53).<list list-type="bullet"><list-item><label/><p id="Par20">APTT: median&#8201;=&#8201;81.6&#160;s; IQR&#8201;=&#8201;66.2&#8211;112.8&#160;s; range&#8201;=&#8201;43.7&#8211;179.9&#160;s.</p></list-item><list-item><label/><p id="Par21">FVIII:C: median&#8201;=&#8201;3.4 IU/dL; IQR&#8201;=&#8201;&lt;&#8201;1.0&#8211;7.8 IU/dL; range&#8201;=&#8201;&lt;&#8201;1.0&#8211;31.1 IU/dL.</p></list-item><list-item><label/><p id="Par22">FVIII inhibitor: median&#8201;=&#8201;34.7 BU/mL; IQR&#8201;=&#8201;14.4&#8211;67.9 BU/mL; range&#8201;=&#8201;1.9&#8211;302.1 BU/mL.</p></list-item></list></p></list-item></list></p></list-item><list-item><p id="Par24">LA group (<italic toggle="yes">n</italic>&#8201;=&#8201;95):<list list-type="bullet"><list-item><label/><p id="Par26">APTT: median&#8201;=&#8201;73.7&#160;s; IQR&#8201;=&#8201;59.1&#8211;87.7&#160;s; range&#8201;=&#8201;38.6&#8211;167.1&#160;s.</p></list-item><list-item><label/><p id="Par27">Normalized ratio in dilute Russell&#8217;s viper venom time (dRVVT): median&#8201;=&#8201;1.66; IQR&#8201;=&#8201;1.43&#8211;1.92; range&#8201;=&#8201;1.21&#8211;4.25.</p></list-item></list></p></list-item><list-item><p id="Par29">UFH group (<italic toggle="yes">n</italic>&#8201;=&#8201;99):<list list-type="bullet"><list-item><label/><p id="Par31">APTT: median&#8201;=&#8201;55.6&#160;s; IQR&#8201;=&#8201;44.5&#8211;70.6&#160;s; range&#8201;=&#8201;35.8&#8211;193.0&#160;s.</p></list-item><list-item><label/><p id="Par32">UFH concentration: median&#8201;=&#8201;0.41 IU/mL; IQR&#8201;=&#8201;0.28&#8211;0.53 IU/mL; range&#8201;=&#8201;0.10&#8211;1.27 IU/mL.</p></list-item></list></p></list-item><list-item><p id="Par34">VKA group (<italic toggle="yes">n</italic>&#8201;=&#8201;105):<list list-type="bullet"><list-item><label/><p id="Par36">APTT: median&#8201;=&#8201;50.0&#160;s; IQR&#8201;=&#8201;45.0&#8211;57.3&#160;s; range&#8201;=&#8201;36.9&#8211;111.4&#160;s.</p></list-item><list-item><label/><p id="Par37">PT international normalized ratio (PT/INR): median&#8201;=&#8201;2.67; IQR&#8201;=&#8201;2.26&#8211;3.58; range&#8201;=&#8201;1.36 to &gt;&#8201;9.00.</p></list-item></list></p></list-item><list-item><p id="Par39">DOACs group (<italic toggle="yes">n</italic>&#8201;=&#8201;249):<list list-type="bullet"><list-item><label/><p id="Par41">Dab samples (<italic toggle="yes">n</italic>&#8201;=&#8201;61).<list list-type="bullet"><list-item><label/><p id="Par42">APTT: median&#8201;=&#8201;49.7&#160;s; IQR&#8201;=&#8201;44.5&#8211;61.6&#160;s; range&#8201;=&#8201;36.8&#8211;196.6&#160;s.</p></list-item><list-item><label/><p id="Par43">Dab concentration: median&#8201;=&#8201;152.4 ng/mL; IQR&#8201;=&#8201;79.3&#8211;216.6 ng/mL; range&#8201;=&#8201;18.4&#8211;593.8 ng/mL.</p></list-item></list></p></list-item><list-item><label/><p id="Par44">Riv samples (<italic toggle="yes">n</italic>&#8201;=&#8201;96).<list list-type="bullet"><list-item><label/><p id="Par45">APTT: median&#8201;=&#8201;41.9&#160;s; IQR&#8201;=&#8201;39.2&#8211;45.6&#160;s; range&#8201;=&#8201;35.9&#8211;78.3&#160;s.</p></list-item><list-item><label/><p id="Par46">Riv concentration: median&#8201;=&#8201;340.9 ng/mL; IQR&#8201;=&#8201;235.2&#8211;436.5 ng/mL; range&#8201;=&#8201;53.5 to &gt;&#8201;527.0 ng/mL.</p></list-item></list></p></list-item><list-item><label/><p id="Par47">Api samples (<italic toggle="yes">n</italic>&#8201;=&#8201;43).<list list-type="bullet"><list-item><label/><p id="Par48">APTT: median&#8201;=&#8201;37.9&#160;s; IQR&#8201;=&#8201;37.0&#8211;39.3&#160;s; range&#8201;=&#8201;35.5&#8211;78.2&#160;s.</p></list-item><list-item><label/><p id="Par49">Api concentration: median&#8201;=&#8201;201.3 ng/mL; IQR&#8201;=&#8201;111.4&#8211;247.0 ng/mL; range&#8201;=&#8201;35.4&#8211;544.1 ng/mL.</p></list-item></list></p></list-item><list-item><label/><p id="Par50">Edo samples (<italic toggle="yes">n</italic>&#8201;=&#8201;49).<list list-type="bullet"><list-item><label/><p id="Par51">APTT: median&#8201;=&#8201;39.9&#160;s; IQR&#8201;=&#8201;37.5&#8211;45.0&#160;s; range&#8201;=&#8201;35.9&#8211;98.8&#160;s.</p></list-item><list-item><label/><p id="Par52">Edo concentration: median&#8201;=&#8201;154.0 ng/mL; IQR&#8201;=&#8201;113.3&#8211;257.0 ng/mL; range&#8201;=&#8201;31.3 to &gt;&#8201;497.0 ng/mL.</p></list-item></list></p></list-item></list></p></list-item></list></p><p id="Par53">The hemophilia group consisted mostly of pre-treatment samples, with some post-treatment samples included. The DOAC samples were collected at random time points (i.e., including both peak and trough levels), and their DOAC concentrations were measured using commercial kits based on the anti-IIa and anti-Xa assays (see Methods section).</p></sec><sec id="Sec4"><title>Adjusted CWA curves</title><p id="Par54">The time-dependent changes in light transmittance during fibrin formation in APTT measurements at 660&#160;nm (usual wavelength) every 0.1&#160;s are represented in a graph, which served as clot waveforms (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>A-left). The first- and second-derivative curves of the clot waveforms were obtained through CWA techniques (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>A-middle, right). Although the three types of curves differed depending on the causes of APTT prolongation, some features (e.g., peak height of the curves) apparently overlapped among the APTT prolongation causes (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>A).</p><p id="Par55">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>CWA curves with and without adjustment in each APTT abnormality. CWA curves include clot waveform and its first- and second-derivative curves. APTT abnormalities consist of hemophilia, lupus anticoagulant (LA), and anticoagulants (unfractionated heparin [UFH], vitamin K antagonist [VKA], and direct oral anticoagulants [DOACs]); wherein the hemophilia and DOAC groups presented in the graph are from a patient with hemophilia A and a patient on dabigatran, respectively. The clot waveforms automatically obtained from the analyzer (<bold>A</bold>-left) were adjusted at maximum value to 100% and minimum value to 0%, which served as adjusted clot waveforms (<bold>B</bold>-left) and their derivative curves were obtained (<bold>B</bold>-middle, right). The CWA curves shown represent one representative sample from each group. <italic toggle="yes">CWA</italic> clot waveform analysis.</p></caption><graphic id="d33e583" position="float" orientation="portrait" xlink:href="41598_2025_15089_Fig1_HTML.jpg"/></fig>
</p><p id="Par56">The adjustment method clearly differentiated the APTT prolongation causes. The adjusted clot waveforms and their first- and second-derivative curves showed larger differences in the shapes (especially the peak height of the curves) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>B), depending on the APTT prolongation causes, compared to the non-adjusted CWA curves. Regarding discriminative ability, we identified that the adjusted CWA parameters (Ad|min1|, Ad|min2|, and Ad_max2) obtained from the adjusted CWA curves showed generally higher area under the curve (AUC) values than those of conventional CWA parameters (|min1|, |min2|, and max2) and APTT (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>), indicating the usefulness of the adjustment method. The effectiveness of the adjustment method was pronounced as indicated by the higher AUC values in LA and DOACs, although the AUC values in hemophilia and UFH were slightly lower compared to those obtained using the non-adjustment (i.e., conventional) method.</p><p id="Par57">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Discriminative ability for five APTT prolongation causes in each quantitative parameter.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="7" rowspan="1">AUC (95% CI)</th></tr><tr><th align="left" colspan="1" rowspan="1">APTT (s)</th><th align="left" colspan="1" rowspan="1">|min1|</th><th align="left" colspan="1" rowspan="1">|min2|</th><th align="left" colspan="1" rowspan="1">max2</th><th align="left" colspan="1" rowspan="1">Ad|min1|</th><th align="left" colspan="1" rowspan="1">Ad|min2|</th><th align="left" colspan="1" rowspan="1">Ad_max2</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Hemophilia</td><td char="." align="char" colspan="1" rowspan="1">0.739 (0.687&#8211;0.790)</td><td char="." align="char" colspan="1" rowspan="1">0.853 (0.812&#8211;0.895)</td><td char="." align="char" colspan="1" rowspan="1">0.858 (0.817&#8211;0.899)</td><td char="." align="char" colspan="1" rowspan="1">0.849 (0.807&#8211;0.891)</td><td char="." align="char" colspan="1" rowspan="1">0.842 (0.799&#8211;0.885)</td><td char="." align="char" colspan="1" rowspan="1">0.841 (0.798&#8211;0.884)</td><td char="." align="char" colspan="1" rowspan="1">0.832 (0.788&#8211;0.876)</td></tr><tr><td align="left" colspan="1" rowspan="1">LA</td><td char="." align="char" colspan="1" rowspan="1">0.769 (0.711&#8211;0.826)</td><td char="." align="char" colspan="1" rowspan="1">0.764 (0.706&#8211;0.822)</td><td char="." align="char" colspan="1" rowspan="1">0.786 (0.729&#8211;0.842)</td><td char="." align="char" colspan="1" rowspan="1">0.789 (0.733&#8211;0.845)</td><td char="." align="char" colspan="1" rowspan="1">0.816 (0.762&#8211;0.869)</td><td char="." align="char" colspan="1" rowspan="1">0.817 (0.763&#8211;0.870)</td><td char="." align="char" colspan="1" rowspan="1">0.805 (0.750&#8211;0.860)</td></tr><tr><td align="left" colspan="1" rowspan="1">UFH</td><td char="." align="char" colspan="1" rowspan="1">0.549 (0.487&#8211;0.612)</td><td char="." align="char" colspan="1" rowspan="1">0.678 (0.617&#8211;0.740)</td><td char="." align="char" colspan="1" rowspan="1">0.594 (0.532&#8211;0.657)</td><td char="." align="char" colspan="1" rowspan="1">0.666 (0.604&#8211;0.728)</td><td char="." align="char" colspan="1" rowspan="1">0.588 (0.525&#8211;0.651)</td><td char="." align="char" colspan="1" rowspan="1">0.523 (0.461&#8211;0.585)</td><td char="." align="char" colspan="1" rowspan="1">0.610 (0.547&#8211;0.673)</td></tr><tr><td align="left" colspan="1" rowspan="1">VKA</td><td char="." align="char" colspan="1" rowspan="1">0.523 (0.462&#8211;0.584)</td><td char="." align="char" colspan="1" rowspan="1">0.532 (0.471&#8211;0.593)</td><td char="." align="char" colspan="1" rowspan="1">0.560 (0.499&#8211;0.621)</td><td char="." align="char" colspan="1" rowspan="1">0.583 (0.522&#8211;0.645)</td><td char="." align="char" colspan="1" rowspan="1">0.600 (0.538&#8211;0.661)</td><td char="." align="char" colspan="1" rowspan="1">0.553 (0.492&#8211;0.615)</td><td char="." align="char" colspan="1" rowspan="1">0.631 (0.570&#8211;0.692)</td></tr><tr><td align="left" colspan="1" rowspan="1">DOACs</td><td char="." align="char" colspan="1" rowspan="1">0.816 (0.780&#8211;0.851)</td><td char="." align="char" colspan="1" rowspan="1">0.765 (0.726&#8211;0.804)</td><td char="." align="char" colspan="1" rowspan="1">0.808 (0.772&#8211;0.844)</td><td char="." align="char" colspan="1" rowspan="1">0.846 (0.813&#8211;0.879)</td><td char="." align="char" colspan="1" rowspan="1">0.906 (0.880&#8211;0.932)</td><td char="." align="char" colspan="1" rowspan="1">0.915 (0.889&#8211;0.940)</td><td char="." align="char" colspan="1" rowspan="1">0.900 (0.873&#8211;0.927)</td></tr></tbody></table><table-wrap-foot><p>Quantitative parameters used were APTT (s), conventional CWA parameters (|min1|, |min2|, max2, obtained from non-adjusted CWA curves), and adjusted CWA parameters (Ad|min1|, Ad|min2|, Ad_max2, obtained from adjusted CWA curves).</p><p><italic toggle="yes">APTT</italic> activated partial thromboplastin time, <italic toggle="yes">AUC</italic> area under the curve, <italic toggle="yes">CWA</italic> clot waveform analysis, <italic toggle="yes">DOACs</italic> direct oral anticoagulants, <italic toggle="yes">LA</italic> lupus anticoagulant, <italic toggle="yes">UFH</italic> unfractionated heparin, <italic toggle="yes">VKA</italic> vitamin K antagonist, <italic toggle="yes">95% Cl</italic> 95% confidence interval.</p></table-wrap-foot></table-wrap>
</p><p id="Par58">Statistical analyses of AUC values revealed the effect of employing the adjustment method. Significant differences were observed between |min1| and Ad|min1| in groups LA, UFH, and DOACs (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001 for each), whereas no significance was found in hemophilia (<italic toggle="yes">P</italic>&#8201;=&#8201;0.381) and VKA (<italic toggle="yes">P</italic>&#8201;=&#8201;0.103). Similarly, comparisons between |min2| and Ad|min2| showed significant differences in LA (<italic toggle="yes">P</italic>&#8201;=&#8201;0.005) and in UFH and DOACs (both <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), but not in hemophilia (<italic toggle="yes">P</italic>&#8201;=&#8201;0.104) or VKA (<italic toggle="yes">P</italic>&#8201;=&#8201;0.864). In contrast, the differences between max2 and Ad_max2 were significant in hemophilia (<italic toggle="yes">P</italic>&#8201;=&#8201;0.024) and in UFH, VKA, and DOACs (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001 for each), while the difference in LA was near-significant (<italic toggle="yes">P</italic>&#8201;=&#8201;0.053). Taken together, the conventional (i.e., non-adjustment) method showed superior performance in four parameter-group combinations, whereas the adjustment method outperformed in six, supporting its utility.</p><p id="Par59">The adjusted CWA parameters showed higher performance than those for conventional methods. However, the sensitivity and specificity for the discrimination of the APTT prolongation causes were slightly short of the requirements for clinical use (e.g., high specificity such as &gt;&#8201;90%<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>)&#8212;with sensitivity of 78.5&#8211;89.6%, 85.3&#8211;90.5%, 63.6&#8211;92.9%, 90.5&#8211;96.2%, and 85.9&#8211;87.6% and specificity of 66.1&#8211;72.3%, 69.4&#8211;74.0%, 25.9&#8211;53.4%, 42.2&#8211;48.6%, and 76.7&#8211;88.2% for hemophilia, LA, UFH, VKA, and DOACs, respectively, depending on the adjusted CWA parameters.</p></sec><sec id="Sec5"><title>DL of adjusted CWA curves</title><p id="Par60">DL of the adjusted CWA curves (i.e., numerical raw data composing the curves) considerably improved the diagnostic performance for APTT abnormalities (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>A). The AUC values of the four DL models constructed using adjusted clot waveforms, their first-derivative curves, second-derivative curves, and all curves were 0.925&#8211;0.982, 0.933&#8211;0.992, 0.949&#8211;0.989, and 0.943&#8211;0.988, respectively; all of which were higher than those of adjusted CWA parameters.</p><p id="Par61">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Prediction accuracy for five APTT prolongation causes in eight deep learning models: (A) four models developed using each type of single-wavelength CWA curve (clot waveforms, first-derivative curves, second-derivative curves, and all combined), and (B) the remaining four models developed using multi-wavelength CWA curves.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="6" rowspan="1">A. DL models constructed using each type of single-wavelength (660&#160;nm) CWA curve</th></tr><tr><th align="left" colspan="2" rowspan="1"/><th align="left" colspan="1" rowspan="1">Clot waveform</th><th align="left" colspan="1" rowspan="1">1st derivative curve</th><th align="left" colspan="1" rowspan="1">2nd derivative curve</th><th align="left" colspan="1" rowspan="1">All curves</th></tr></thead><tbody><tr><td align="left" rowspan="3" colspan="1">Hemophilia</td><td align="left" colspan="1" rowspan="1">AUC (95% CI)</td><td char="." align="char" colspan="1" rowspan="1">0.982 (0.966&#8211;0.998)</td><td char="." align="char" colspan="1" rowspan="1">0.968 (0.947&#8211;0.989)</td><td char="." align="char" colspan="1" rowspan="1">0.983 (0.968&#8211;0.998)</td><td char="." align="char" colspan="1" rowspan="1">0.988 (0.974&#8211;1.000)</td></tr><tr><td align="left" colspan="1" rowspan="1">Sensitivity</td><td char="." align="char" colspan="1" rowspan="1">94.1%</td><td char="." align="char" colspan="1" rowspan="1">99.3%</td><td char="." align="char" colspan="1" rowspan="1">97.0%</td><td char="." align="char" colspan="1" rowspan="1">98.5%</td></tr><tr><td align="left" colspan="1" rowspan="1">Specificity</td><td char="." align="char" colspan="1" rowspan="1">92.9%</td><td char="." align="char" colspan="1" rowspan="1">85.2%</td><td char="." align="char" colspan="1" rowspan="1">92.7%</td><td char="." align="char" colspan="1" rowspan="1">93.6%</td></tr><tr><td align="left" rowspan="3" colspan="1">LA</td><td align="left" colspan="1" rowspan="1">AUC (95% CI)</td><td char="." align="char" colspan="1" rowspan="1">0.946 (0.914&#8211;0.978)</td><td char="." align="char" colspan="1" rowspan="1">0.933 (0.897&#8211;0.968)</td><td char="." align="char" colspan="1" rowspan="1">0.949 (0.918&#8211;0.980)</td><td char="." align="char" colspan="1" rowspan="1">0.943 (0.910&#8211;0.976)</td></tr><tr><td align="left" colspan="1" rowspan="1">Sensitivity</td><td char="." align="char" colspan="1" rowspan="1">89.5%</td><td char="." align="char" colspan="1" rowspan="1">94.7%</td><td char="." align="char" colspan="1" rowspan="1">89.5%</td><td char="." align="char" colspan="1" rowspan="1">93.7%</td></tr><tr><td align="left" colspan="1" rowspan="1">Specificity</td><td char="." align="char" colspan="1" rowspan="1">90.8%</td><td char="." align="char" colspan="1" rowspan="1">82.7%</td><td char="." align="char" colspan="1" rowspan="1">88.6%</td><td char="." align="char" colspan="1" rowspan="1">83.3%</td></tr><tr><td align="left" rowspan="3" colspan="1">UFH</td><td align="left" colspan="1" rowspan="1">AUC (95% CI)</td><td char="." align="char" colspan="1" rowspan="1">0.925(0.889&#8211;0.961)</td><td char="." align="char" colspan="1" rowspan="1">0.977 (0.956&#8211;0.998)</td><td char="." align="char" colspan="1" rowspan="1">0.979 (0.959&#8211;0.999)</td><td char="." align="char" colspan="1" rowspan="1">0.959 (0.931&#8211;0.986)</td></tr><tr><td align="left" colspan="1" rowspan="1">Sensitivity</td><td char="." align="char" colspan="1" rowspan="1">87.9%</td><td char="." align="char" colspan="1" rowspan="1">96.0%</td><td char="." align="char" colspan="1" rowspan="1">96.0%</td><td char="." align="char" colspan="1" rowspan="1">83.8%</td></tr><tr><td align="left" colspan="1" rowspan="1">Specificity</td><td char="." align="char" colspan="1" rowspan="1">79.8%</td><td char="." align="char" colspan="1" rowspan="1">92.1%</td><td char="." align="char" colspan="1" rowspan="1">93.0%</td><td char="." align="char" colspan="1" rowspan="1">96.4%</td></tr><tr><td align="left" rowspan="3" colspan="1">VKA</td><td align="left" colspan="1" rowspan="1">AUC (95% CI)</td><td char="." align="char" colspan="1" rowspan="1">0.982 (0.964&#8211;1.000)</td><td char="." align="char" colspan="1" rowspan="1">0.992 (0.980&#8211;1.000)</td><td char="." align="char" colspan="1" rowspan="1">0.989 (0.974&#8211;1.000)</td><td char="." align="char" colspan="1" rowspan="1">0.984 (0.967&#8211;1.000)</td></tr><tr><td align="left" colspan="1" rowspan="1">Sensitivity</td><td char="." align="char" colspan="1" rowspan="1">97.1%</td><td char="." align="char" colspan="1" rowspan="1">97.1%</td><td char="." align="char" colspan="1" rowspan="1">97.1%</td><td char="." align="char" colspan="1" rowspan="1">97.1%</td></tr><tr><td align="left" colspan="1" rowspan="1">Specificity</td><td char="." align="char" colspan="1" rowspan="1">96.5%</td><td char="." align="char" colspan="1" rowspan="1">99.1%</td><td char="." align="char" colspan="1" rowspan="1">99.7%</td><td char="." align="char" colspan="1" rowspan="1">98.4%</td></tr><tr><td align="left" rowspan="3" colspan="1">DOACs</td><td align="left" colspan="1" rowspan="1">AUC (95% CI)</td><td char="." align="char" colspan="1" rowspan="1">0.932 (0.909&#8211;0.954)</td><td char="." align="char" colspan="1" rowspan="1">0.962 (0.945&#8211;0.979)</td><td char="." align="char" colspan="1" rowspan="1">0.959 (0.941&#8211;0.977)</td><td char="." align="char" colspan="1" rowspan="1">0.946 (0.926&#8211;0.966)</td></tr><tr><td align="left" colspan="1" rowspan="1">Sensitivity</td><td char="." align="char" colspan="1" rowspan="1">82.3%</td><td char="." align="char" colspan="1" rowspan="1">89.6%</td><td char="." align="char" colspan="1" rowspan="1">89.6%</td><td char="." align="char" colspan="1" rowspan="1">85.9%</td></tr><tr><td align="left" colspan="1" rowspan="1">Specificity</td><td char="." align="char" colspan="1" rowspan="1">92.6%</td><td char="." align="char" colspan="1" rowspan="1">92.4%</td><td char="." align="char" colspan="1" rowspan="1">94.9%</td><td char="." align="char" colspan="1" rowspan="1">94.9%</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="6" rowspan="1">B. DL models constructed using each type of multi-wavelength CWA curve</th></tr><tr><th align="left" colspan="2" rowspan="1"/><th align="left" colspan="1" rowspan="1">Clot waveform</th><th align="left" colspan="1" rowspan="1">1st derivative curve</th><th align="left" colspan="1" rowspan="1">2nd derivative curve</th><th align="left" colspan="1" rowspan="1">All curves</th></tr></thead><tbody><tr><td align="left" rowspan="3" colspan="1">&#160;Hemophilia</td><td align="left" colspan="1" rowspan="1">AUC (95% CI)</td><td char="." align="char" colspan="1" rowspan="1">0.985 (0.970&#8211;0.999)</td><td char="." align="char" colspan="1" rowspan="1">0.967 (0.945&#8211;0.988)</td><td char="." align="char" colspan="1" rowspan="1">0.982 (0.967&#8211;0.998)</td><td char="." align="char" colspan="1" rowspan="1">0.993 (0.983&#8211;1.000)</td></tr><tr><td align="left" colspan="1" rowspan="1">Sensitivity</td><td char="." align="char" colspan="1" rowspan="1">96.3%</td><td char="." align="char" colspan="1" rowspan="1">94.8%</td><td char="." align="char" colspan="1" rowspan="1">&gt;&#8201;99.9%</td><td char="." align="char" colspan="1" rowspan="1">98.5%</td></tr><tr><td align="left" colspan="1" rowspan="1">Specificity</td><td char="." align="char" colspan="1" rowspan="1">93.6%</td><td char="." align="char" colspan="1" rowspan="1">88.0%</td><td char="." align="char" colspan="1" rowspan="1">92.2%</td><td char="." align="char" colspan="1" rowspan="1">94.3%</td></tr><tr><td align="left" rowspan="3" colspan="1">LA</td><td align="left" colspan="1" rowspan="1">AUC (95% CI)</td><td char="." align="char" colspan="1" rowspan="1">0.959 (0.931&#8211;0.987)</td><td char="." align="char" colspan="1" rowspan="1">0.940 (0.907&#8211;0.974)</td><td char="." align="char" colspan="1" rowspan="1">0.944 (0.912&#8211;0.977)</td><td char="." align="char" colspan="1" rowspan="1">0.967 (0.942&#8211;0.993)</td></tr><tr><td align="left" colspan="1" rowspan="1">Sensitivity</td><td char="." align="char" colspan="1" rowspan="1">92.6%</td><td char="." align="char" colspan="1" rowspan="1">93.7%</td><td char="." align="char" colspan="1" rowspan="1">92.6%</td><td char="." align="char" colspan="1" rowspan="1">93.7%</td></tr><tr><td align="left" colspan="1" rowspan="1">Specificity</td><td char="." align="char" colspan="1" rowspan="1">91.3%</td><td char="." align="char" colspan="1" rowspan="1">84.5%</td><td char="." align="char" colspan="1" rowspan="1">84.7%</td><td char="." align="char" colspan="1" rowspan="1">93.4%</td></tr><tr><td align="left" rowspan="3" colspan="1">UFH</td><td align="left" colspan="1" rowspan="1">AUC (95% CI)</td><td char="." align="char" colspan="1" rowspan="1">0.951 (0.921&#8211;0.981)</td><td char="." align="char" colspan="1" rowspan="1">0.975 (0.954&#8211;0.997)</td><td char="." align="char" colspan="1" rowspan="1">0.976 (0.955&#8211;0.977)</td><td char="." align="char" colspan="1" rowspan="1">0.969 (0.946&#8211;0.993)</td></tr><tr><td align="left" colspan="1" rowspan="1">Sensitivity</td><td char="." align="char" colspan="1" rowspan="1">92.9%</td><td char="." align="char" colspan="1" rowspan="1">92.9%</td><td char="." align="char" colspan="1" rowspan="1">96.0%</td><td char="." align="char" colspan="1" rowspan="1">94.9%</td></tr><tr><td align="left" colspan="1" rowspan="1">Specificity</td><td char="." align="char" colspan="1" rowspan="1">82.9%</td><td char="." align="char" colspan="1" rowspan="1">95.4%</td><td char="." align="char" colspan="1" rowspan="1">94.7%</td><td char="." align="char" colspan="1" rowspan="1">92.1%</td></tr><tr><td align="left" rowspan="3" colspan="1">VKA</td><td align="left" colspan="1" rowspan="1">AUC (95% CI)</td><td char="." align="char" colspan="1" rowspan="1">0.978 (0.958&#8211;0.998)</td><td char="." align="char" colspan="1" rowspan="1">0.989 (0.975&#8211;1.000)</td><td char="." align="char" colspan="1" rowspan="1">0.986 (0.970&#8211;1.000)</td><td char="." align="char" colspan="1" rowspan="1">0.988 (0.974&#8211;1.000)</td></tr><tr><td align="left" colspan="1" rowspan="1">Sensitivity</td><td char="." align="char" colspan="1" rowspan="1">92.4%</td><td char="." align="char" colspan="1" rowspan="1">97.1%</td><td char="." align="char" colspan="1" rowspan="1">98.1%</td><td char="." align="char" colspan="1" rowspan="1">98.1%</td></tr><tr><td align="left" colspan="1" rowspan="1">Specificity</td><td char="." align="char" colspan="1" rowspan="1">97.6%</td><td char="." align="char" colspan="1" rowspan="1">98.8%</td><td char="." align="char" colspan="1" rowspan="1">98.8%</td><td char="." align="char" colspan="1" rowspan="1">99.1%</td></tr><tr><td align="left" rowspan="3" colspan="1">DOACs</td><td align="left" colspan="1" rowspan="1">AUC (95% CI)</td><td char="." align="char" colspan="1" rowspan="1">0.938 (0.916&#8211;0.959)</td><td char="." align="char" colspan="1" rowspan="1">0.957 (0.938&#8211;0.975)</td><td char="." align="char" colspan="1" rowspan="1">0.959 (0.941&#8211;0.977)</td><td char="." align="char" colspan="1" rowspan="1">0.961 (0.944&#8211;0.979)</td></tr><tr><td align="left" colspan="1" rowspan="1">Sensitivity</td><td char="." align="char" colspan="1" rowspan="1">82.7%</td><td char="." align="char" colspan="1" rowspan="1">91.2%</td><td char="." align="char" colspan="1" rowspan="1">88.0%</td><td char="." align="char" colspan="1" rowspan="1">88.0%</td></tr><tr><td align="left" colspan="1" rowspan="1">Specificity</td><td char="." align="char" colspan="1" rowspan="1">92.2%</td><td char="." align="char" colspan="1" rowspan="1">92.6%</td><td char="." align="char" colspan="1" rowspan="1">94.0%</td><td char="." align="char" colspan="1" rowspan="1">96.5%</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">APTT</italic> activated partial thromboplastin time, <italic toggle="yes">AUC</italic> area under the curve, <italic toggle="yes">CWA</italic> clot waveform analysis, <italic toggle="yes">DOACs</italic> direct oral anticoagulants, <italic toggle="yes">LA</italic> lupus anticoagulant, <italic toggle="yes">UFH</italic> unfractionated heparin, <italic toggle="yes">VKA</italic> vitamin K antagonist, <italic toggle="yes">95% Cl</italic> 95% confidence interval.</p></table-wrap-foot></table-wrap>
</p><p id="Par62">Statistical analyses confirmed the superiority of the DL techniques. Significant differences in AUC values were observed between Ad|min1| and the DL model developed using the adjusted first-derivative curves, Ad|min2| and the DL model using the adjusted second-derivative curves, and Ad_max2 and the DL model using the adjusted second-derivative curves across all groups (hemophilia, LA, UFH, VKA, and DOACs) (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001 for each comparison).</p><p id="Par63">The sensitivity and specificity of the four models were also increased. The sensitivities were 82.3&#8211;97.1%, 89.6&#8211;99.3%, 89.5&#8211;97.1%, and 83.8&#8211;98.5%, and the specificities were 79.8&#8211;96.5%, 82.7&#8211;99.1%, 88.6&#8211;99.7%, and 83.3&#8211;98.4%, for the DL models developed using clot waveforms, their first-derivative curves, second-derivative curves, and all curves, respectively.</p></sec><sec id="Sec6"><title>Multi-wavelength CWA</title><p id="Par64">Adjusted clot waveforms and their first- and second-derivative curves obtained using the multi-wavelength detection system provided unique characteristics in their shapes depending on the wavelengths and APTT prolongation causes (Figs.&#160;<xref rid="Fig2" ref-type="fig">2</xref> and <xref rid="Fig3" ref-type="fig">3</xref>). The differences in the Ad|min1| peak height among the APTT abnormalities were pronounced at 405&#160;nm (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>A), whereas the group differences were quite small at other wavelengths (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>B, C, D). The hemophilia samples showed different shapes in the second-derivative curves in the coagulation deceleration phase between 575&#160;nm and 800&#160;nm (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>A). However, these differences between the wavelengths were small in LA, UFH, VKA and DOACs samples (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>B, C, D, E). Considering the unique features, DL of multi-wavelength CWA data can increase the prediction accuracy of the DL models.</p><p id="Par65">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Differences in adjusted CWA curves among APTT abnormalities at various wavelengths. The wavelengths used were 405&#160;nm (<bold>A</bold>), 575&#160;nm (<bold>B</bold>), 660&#160;nm (<bold>C</bold>), and 800&#160;nm (<bold>D</bold>). The CWA curves shown represent one representative sample from each group, different from those shown in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>. The Hemophilia and DOAC samples shown were from hemophilia A and edoxaban, respectively. <italic toggle="yes">CWA</italic> clot waveform analysis, <italic toggle="yes">DOACs</italic> direct oral anticoagulants, <italic toggle="yes">LA</italic> lupus anticoagulant, <italic toggle="yes">UFH</italic> unfractionated heparin, <italic toggle="yes">VKA</italic> vitamin K antagonist.</p></caption><graphic id="d33e1291" position="float" orientation="portrait" xlink:href="41598_2025_15089_Fig2_HTML.jpg"/></fig>
</p><p id="Par66">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Effect of multi-wavelength measurements depending on each APTT abnormality. The CWA curves represent representative samples from each group&#8212;hemophilia (<bold>A</bold>), LA (<bold>B</bold>), and anticoagulant therapy with UFH (<bold>C</bold>), VKA (<bold>D</bold>), and DOACs (<bold>E</bold>)&#8212;which are the same samples used in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>. <italic toggle="yes">DOACs</italic> direct oral anticoagulants, <italic toggle="yes">LA</italic> lupus anticoagulant, <italic toggle="yes">UFH</italic> unfractionated heparin, <italic toggle="yes">VKA</italic> vitamin K antagonist.</p></caption><graphic id="d33e1333" position="float" orientation="portrait" xlink:href="41598_2025_15089_Fig3_HTML.jpg"/></fig>
</p><p id="Par67">The DL models constructed using multi-wavelength CWA curves showed superior performance compared to those using single-wavelength curves (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>B). The AUC values of the four DL models developed using adjusted clot waveforms, their first-derivative curves, second-derivative curves, and all curves at multiple wavelengths were 0.938&#8211;0.985, 0.940&#8211;0.989, 0.944&#8211;0.986, and 0.961&#8211;0.993, respectively; hence, the DL model developed using all adjusted CWA curves (i.e., clot waveforms, first- and second-derivative curves at multiple wavelengths) showed the highest AUC values (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). Statistical analyses of the AUC values also confirmed the outperformance of the multi-wavelength CWA techniques: significant differences were observed between the DL models developed using the single- and multi-wavelength CWA curves in LA (<italic toggle="yes">P</italic>&#8201;=&#8201;0.018), VKA (<italic toggle="yes">P</italic>&#8201;=&#8201;0.048), and DOACs (<italic toggle="yes">P</italic>&#8201;=&#8201;0.004), a near-significant difference in hemophilia (<italic toggle="yes">P</italic>&#8201;=&#8201;0.063), but no significant difference in UFH (<italic toggle="yes">P</italic>&#8201;=&#8201;0.169). The DL model with the best performance had quite high prediction accuracy; the sensitivity and specificity for the five APTT prolongation causes were 88.0&#8211;98.5% and 92.1&#8211;99.1%, respectively.</p><p id="Par68">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>ROC curves of each classification parameter/model in five APTT prolongation causes. The classification parameters/models presented are APTT (s) (black lines), Ad|min1| (green lines), Ad|min2| (yellow lines), Ad_max2 (red lines), and DL model developed using all (three) adjusted CWA curves at single (660&#160;nm, orange lines) or multiple wavelengths (blue lines). <italic toggle="yes">APTT</italic> activated partial thromboplastin time, <italic toggle="yes">CWA</italic> clot waveform analysis, <italic toggle="yes">DL</italic> deep learning, <italic toggle="yes">DOACs</italic> direct oral anticoagulants, <italic toggle="yes">LA</italic> lupus anticoagulant, <italic toggle="yes">ROC</italic> receiver operating characteristic, <italic toggle="yes">UFH</italic> unfractionated heparin, <italic toggle="yes">VKA</italic> vitamin K antagonist.</p></caption><graphic id="d33e1393" position="float" orientation="portrait" xlink:href="41598_2025_15089_Fig4_HTML.jpg"/></fig>
</p><p id="Par69">The best DL model was little influenced by lot-to-lot differences in the APTT reagents. The AUC differences for the five APTT prolongation causes among the three lots were &#8722;&#8201;0.012 to +&#8201;0.011. The differences in sensitivity and specificity were &#8722;&#8201;3.7% to +&#8201;4.2% and &#8722;&#8201;3.9% to +&#8201;3.3%, respectively.</p></sec><sec id="Sec7"><title>Usefulness of DL models</title><p id="Par70">The DL model with the best performance was applied to another 53 samples with APTT prolongation and either a hemophilia diagnosis (<italic toggle="yes">n</italic>&#8201;=&#8201;13), LA diagnosis (<italic toggle="yes">n</italic>&#8201;=&#8201;10), or anticoagulant therapy using UFH, VKA, or DOACs (<italic toggle="yes">n</italic>&#8201;=&#8201;10 each). The diagnostic performance was as follows: the sensitivity was 100.0%, 100.0%, 100.0%, 100.0%, and 90.0% and specificity was 80.0%, 86.0%, 81.4%, 97.7%, and 90.7% for hemophilia, LA, UFH, VKA, and DOACs, respectively. As controls for the DL model in terms of practical diagnostic tools for APTT abnormalities in clinical settings, mixing tests were performed on the samples. Although the mixing test cannot identify the UFH and DOACs as APTT prolongation causes because of its principle, the diagnostic accuracy for hemophilia, LA, and VKA samples were 92.3%, 60.0%, and 100.0%, respectively. The samples in which LA could not be diagnosed by the mixing tests&#8212;due to the inherent limitation of the method (i.e., the dilution effect)&#8212;included those with mild APTT prolongation (around 50&#160;s): however, the DL model yielded high prediction values of approximately 0.9 for LA in these samples.</p></sec></sec><sec id="Sec8"><title>Discussion</title><p id="Par71">We developed a DL model that classified APTT prolongation causes into five categories, distinguishing between bleeding and thrombotic risks while also classifying the use of three types of anticoagulants. The model demonstrated high sensitivity (&#8805;&#8201;88.0%) and specificity (&gt;&#8201;92.0%). A back-propagation neural network technique using nine conventional CWA parameters was previously reported, but it achieved moderate sensitivity (&gt;&#8201;60%) and high specificity (&gt;&#8201;90%)<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. Furthermore, the model could not identify LA and anticoagulants as APTT prolongation causes and could only distinguish samples as either coagulation factor deficient or non-deficient. Another recent study created a flowchart model using three unique quantitative CWA parameters, achieving 75% accuracy in classifying APTT prolongation causes into six categories (LA, UFH, DOACs, AHA, factor deficiencies, and hepatic dysfunction)<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. In contrast, our study utilized all raw data from three CWA curves, not just selected parameters, resulting in a DL model with superior discrimination performance. While our approach uses full raw data, the data size (approximately 120 KB) and computation time (approximately 0.1&#160;s) per sample were minimal, and the analysis was completed on a commercially available laptop computer rather than a high-performance workstation, resulting in negligible storage and computational burden, minimal impact on turnaround time, and thus supporting feasibility in typical clinical settings.</p><p id="Par72">Our DL model can be a first-line tool for screening APTT prolongation causes. Currently, the mixing test is the primary first-line tool in clinical settings; however, this test has several shortcomings due to requiring incubation (increasing the time needed) and only being able to distinguish bleeding and thrombotic risks<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref></sup>. Furthermore, the test requires mixing with normal plasma to patient plasma, causing dilution effect (i.e., decrease in inhibitor titer): therefore, the mixing test can be difficult to detect inhibitors such as LA in samples with mild APTT prolongation<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. The DL model constructed in the present study overcame these limitations. The model proposes the causes of APTT prolongation while measuring APTT and can differentiate between bleeding- and thrombotic-risks and three types of anticoagulants. Furthermore, the model analyzes coagulation processes in neat test samples (i.e., not alter the samples) and showed superior performance to the mixing test in terms of LA diagnosis. As this method does not require additional equipment (e.g., reagents and analyzers), indicating further advantage in terms of cost, the DL model can be used as a rapid screening tool in clinical settings.</p><p id="Par73">CWA curves, which consist of thousands of numerical values representing optical changes during fibrin formation, provided comprehensive data that contributed to our model&#8217;s high performance. This is the first study to employ a multi-wavelength CWA technique for developing a DL model to identify APTT prolongation causes. Traditional visual interpretation of CWA curve shapes can be challenging, especially for curves with similar shapes. The DL technique can overcome these limitations by detecting subtle features that are not visually discernible. Unique shapes in CWA curves, such as biphasic and shoulder types, have been reported for various causes of APTT prolongation<sup><xref ref-type="bibr" rid="CR15">15</xref>&#8211;<xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR23">23</xref></sup>, which were found in our samples (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>A). However, these visual features are not always reliable in clinical settings due to overlapping characteristics, such as atypical peaks in second-derivative curves observed in both LA-positive and VKA-taking patients<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. Our study also found similar CWA curve shapes regardless of APTT prolongation causes (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>B): the shapes were apparently different from the shape obtained from normal sample, but it was quite difficult to discriminate them visually. The DL model constructed in this study effectively assessed CWA curves and correctly classified the APTT prolongation causes for samples showing unique CWA shapes and those with visually indiscernible shapes, highlighting the technique&#8217;s utility in leveraging hidden features for accurate identification.</p><p id="Par74">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Differential CWA curve shapes depending on APTT abnormalities and samples. Conventional (i.e., not adjusted) clot waveforms and their first- and second-derivative curves at usual (660&#160;nm) wavelength, which are available in automated coagulation analyzers in routine tests, are presented. Unique shapes were identified depending on the APTT prolongation causes (<bold>A</bold>, black lines), whereas similar shapes were also observed regardless of the causes in clinical settings (<bold>B</bold>, black lines). Clot waveform in normal plasma and its first- and second-derivative curves are presented as reference (thin gray lines). <italic toggle="yes">APTT</italic> activated partial thromboplastin time, <italic toggle="yes">CWA</italic> clot waveform analysis, <italic toggle="yes">DOACs</italic> direct oral anticoagulants, <italic toggle="yes">LA</italic> lupus anticoagulant, <italic toggle="yes">UFH</italic> unfractionated heparin, <italic toggle="yes">VKA</italic> vitamin K antagonist.</p></caption><graphic id="d33e1491" position="float" orientation="portrait" xlink:href="41598_2025_15089_Fig5_HTML.jpg"/></fig>
</p><p id="Par75">Each CWA curve uniquely contributed to the prediction accuracy for APTT prolongation causes; hence, the use of all CWA curves resulted in the best performance. First- and second-derivative curves have shown distinct characteristics for different anticoagulants and coagulation disorders<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR25">25</xref></sup>, where first-derivative curves are useful for VKA and DOACs, while second-derivative curves are beneficial for hemophilia, LA, and UFH. Our results are consistent with these previous studies, as indicated by the higher AUC values (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>A). The original clot waveform and its derivative curves individually achieved higher sensitivity and specificity, depending on the causes of APTT prolongation (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>A), confirming that using all CWA curves enhances the diagnostic performance. Interestingly, multi-wavelength CWA further increased classification accuracy (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>B), leading to a DL model with high sensitivity (&#8805;&#8201;88.0%) while maintaining high specificity (&gt;&#8201;92.0%). The introduction of multiple wavelengths allowed for higher absorbance in lower wavelengths and higher signal-to-noise ratio in higher wavelengths<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. Our study also found higher values in peak height at lower wavelengths, contributing to differentiate APTT prolongation causes (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). Furthermore, the CWA curve shapes differed depending on the wavelengths in each APTT prolongation cause (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>), which also contributed to the unique features depending on the causes, indicating effectiveness of introducing the multi-wavelength detection system in obtaining CWA curves. Although wavelengths&#8201;&gt;&#8201;600&#160;nm are preferable for avoiding HIL interference<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>, the multi-wavelength approach provides additional information on APTT CWA abnormalities that warrant further investigation.</p><p id="Par76">The use of conventional CWA parameters has limited efficacy in discriminating APTT prolongation causes. Although APTT reagents have varying sensitivities to coagulation factor deficiencies, LA, and anticoagulants<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>, it is challenging to differentiate between them using APTT values alone, as indicated by the lower AUC values. CWA parameters demonstrated higher performance, and adjusted CWA parameters exhibited higher AUC values; however, they did not reach the levels of the DL models. Therefore, developing a classification model with high clinical applicability using only CWA parameters is difficult. Although combining CWA parameters might enhance performance accuracy, this approach&#8217;s effects would be limited as these parameters represent only a portion of the CWA curve data.</p><p id="Par77">This study has some limitations. The performance of the DL model may be affected by the APTT reagents and/or analyzers used. Different APTT reagents and analyzers can yield different CWA curves<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup>. Consequently, our DL model cannot be directly applied to CWA data obtained with other reagents and analyzers, necessitating the construction of separate DL models for each reagent and analyzer. Although lot-to-lot differences were minimal with the reagent used to develop the DL model, they might be pronounced with other reagents, requiring further examination for each case. Although we attempted to build a separate model distinguishing congenital and acquired hemophilia, the specificity for AHA was relatively low (82.4%) despite high sensitivity (94.3%), and misclassification occurred, possibly due to the relatively small number of AHA samples (<italic toggle="yes">n</italic>&#8201;=&#8201;53) and their clinical heterogeneity (e.g., varying FVIII:C levels and FVIII inhibitor titers), highlighting the need for further studies with large sample sizes to improve classification of bleeding risks in these subtypes. However, as many modern automated coagulation analyzers are equipped with multi-wavelength detection system<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>, integration of the DL analysis into current analyzers using multi-wavelength CWA techniques is technically feasible and widely applicable. This is supported by the fact that the DL analyses were successfully performed on a standard commercially available laptop computer with minimal data storage requirements and high processing speed.</p><p id="Par78">In conclusion, CWA is a potentially promising tool for identifying the causes of APTT prolongation without further testing, which is advantageous in terms of cost and time. However, the CWA parameters, which are part of the data in the CWA curves, have limited ability to discriminate between the causes. To utilize the huge amount of data hidden in the curves, we applied the DL technique to raw CWA data obtained with the multi-wavelength detection system, resulting in the development of a DL model with high sensitivity and specificity. For future directions, considering the variability among APTT reagents and analyzers, the use of DL and multi-wavelength CWA techniques is recommended to develop a rapid screening assay with high accuracy for APTT abnormalities for each APTT reagent and analyzer.</p></sec><sec id="Sec9"><title>Methods</title><sec id="Sec10"><title>Sample preparation</title><p id="Par79">The collected clinical plasma samples were prepared as follows: blood samples for routine coagulation tests were collected using 1.8 mL tubes containing 0.109&#160;M sodium citrate solution, which were then centrifuged following international guidelines<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. After routine tests, the residual plasma was re-centrifuged, then stored at &#8722;&#8201;80&#8451; until use.</p><p id="Par80">This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Niigata University (no. 2020&#8201;&#8722;&#8201;0355), Tenri University (no. 144), Tenri Hospital (no. 1180), and Sysmex Corporation (no. 2020&#8201;&#8722;&#8201;255). Informed consent was obtained using an opt-out method, with information provided on the institution&#8217;s website.</p></sec><sec id="Sec11"><title>Instruments and reagents</title><p id="Par81">We conducted eight types of coagulation tests: APTT, PT, dRVVT, anti-IIa assays, anti-Xa assays, FVIII:C, FIX:C, and the Bethesda assay; the FIX:C and Bethesda assays were outsourced to SRL Inc. (Japan), and the others were performed in our laboratories using an automated blood coagulation analyzer CN-6000 (Sysmex, Japan). The anti-IIa assays were performed to determine Dab concentrations and the anti-Xa assays were performed to determine UFH, Riv, Api, and Edo concentrations.</p><p id="Par82">The reagents used for APTT, PT, dRVVT, FVIII:C, anti-IIa assays, and anti-Xa assays were as follows: Revohem APTT SLA, Revohem PT, LA Reagent DRVVT, Revohem FVIII Chromogenic (Sysmex), BIOPHEN DTI, and BIOPHEN Heparin LRT (Hyphen Biomed, France). The APTT was measured using three lots of the reagent in all samples to examine the influence of lot-to-lot differences on the developed DL model. Based on the dRVVT assay, we calculated the normalized ratio, in which&#8201;&gt;&#8201;1.20 was used as criterion for LA diagnosis. Anti-IIa and anti-Xa assays used UFH and DOAC calibrators (Hyphen Biomed) to calculate UFH and DOAC concentrations in the samples.</p></sec><sec id="Sec12"><title>CWA data acquisition</title><p id="Par83">APTT-based CWA data were obtained as follows. The changes in light transmittance during fibrin formation in APTT measurements were automatically recorded every 0.1&#160;s at multiple wavelengths of 340, 405, 575, 660, and 800&#160;nm on the analyzer. Although the analyzer recorded the data at five wavelengths, we used data at four wavelengths (omitting 340&#160;nm) owing to the signal-to-noise ratio, as the signal variability in the pre-coagulation phase at 340&#160;nm was approximately twice as high as the other wavelengths in a preliminary test using 25 normal samples. The curves generated using the data of time-dependent changes at every wavelength were used as clot waveforms, and those adjusted at the maximum value to 100% and minimum value to 0% were used as adjusted clot waveforms<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. The first- and second-derivative curves of the clot waveforms with and without adjustment were then obtained. The raw data (i.e., numerical values, not images) of the CWA curves were used as the CWA data for constructing the DL models. In addition, the conventional CWA parameters, namely, |min1|/Ad|min1| (reflecting coagulation velocity), |min2|/Ad|min2| (maximum coagulation acceleration), and max2/Ad_max2 (maximum coagulation deceleration), were obtained using a standard data processing algorithm pre-installed in the analyzer.</p></sec><sec id="Sec13"><title>DL model construction and validation</title><p id="Par84">For constructing the DL model, we used a CNN technique<sup><xref ref-type="bibr" rid="CR29">29</xref>&#8211;<xref ref-type="bibr" rid="CR31">31</xref></sup>. A CNN is useful for constructing classification models because the technique allows for the automatic extraction of meaningful features, multitasking, and hierarchical learning, which contribute to the automatic acquisition of optimized parameters of weights and biases through numerous learning processes. CNNs have been widely used in many fields<sup><xref ref-type="bibr" rid="CR32">32</xref>&#8211;<xref ref-type="bibr" rid="CR34">34</xref></sup>, particularly in radiology, and good sensitivity and specificity have been reported<sup><xref ref-type="bibr" rid="CR35">35</xref>&#8211;<xref ref-type="bibr" rid="CR37">37</xref></sup>; however, they have not been used in coagulopathy screening for bleeding and thrombotic risks. To our knowledge, this is the first study to introduce a CNN technique for classifying coagulation abnormalities based on APTT prolongation. We used TensorFlow (version 2.13.0), an open-source software in Google<sup><xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR39">39</xref></sup>. The structure of the implemented CNN, which has four convolutional layers, is shown in Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>.</p><p id="Par85">
<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>Structure of convolutional neural network (CNN). <italic toggle="yes">DOACs</italic> direct oral anticoagulants, <italic toggle="yes">Flatten</italic> flattened layer, <italic toggle="yes">Full Connect</italic> fully connected layer, <italic toggle="yes">LA</italic> lupus anticoagulant, <italic toggle="yes">Max Pool</italic> max pooling layer, <italic toggle="yes">ReLU</italic> rectified linear unit, <italic toggle="yes">Softmax</italic> softmax function, <italic toggle="yes">UFH</italic> unfractionated heparin, <italic toggle="yes">VKA</italic> vitamin K antagonist, <italic toggle="yes">1D Conv</italic> 1 dimensional convolution layer.</p></caption><graphic id="d33e1657" position="float" orientation="portrait" xlink:href="41598_2025_15089_Fig6_HTML.jpg"/></fig>
</p><p id="Par86">We constructed eight types of DL models by combining four types of CWA data (clot waveforms, first-derivative curves, second-derivative curves, and all curves) with two types of wavelengths (660&#160;nm and multiple wavelengths). The DL models were developed based on the Youden index<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. To evaluate the performance of the models, 10-fold cross-validation was employed. Data from all samples were mixed and randomly divided (without stratified sampling) into 10 folds with nearly equal sample size (68&#8211;69 samples each). Each fold contained a distribution of the five groups (hemophilia, LA, UFH, VKA, and DOACs) that was approximately proportional to the overall sample composition. In each iteration, nine folds were used for training, and the remaining fold was used for validation, ensuring that each fold served as validation data once. The AUC, sensitivity, and specificity were used to assess prediction accuracy. The DL model that showed the best performance was validated for lot-to-lot differences in APTT reagents, in which AUC, sensitivity, and specificity were calculated by inputting CWA data obtained using two other lot reagents (not used for model construction) into the best DL model. Additionally, the conventional quantitative parameters of |min1|/Ad|min1|, |min2|/Ad|min2|, and max2/Ad_max2, including APTT obtained using usual single-wavelength measurements at 660&#160;nm, were evaluated for their ability to distinguish the causes of APTT prolongation, using the roc_curve function in the scikit-learn library (version 1.1.2)<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>.</p></sec><sec id="Sec14"><title>Mixing test</title><p id="Par87">Mixing tests were performed on 53 other samples (i.e., not used for DL model construction) to examine and compare diagnostic performance for APTT prolongation to that of the DL model. The samples were from patients who exhibited APTT prolongation and either a hemophilia diagnosis (<italic toggle="yes">n</italic>&#8201;=&#8201;13; 8 HA, 3 HB, and 2 AHA samples, APTT: 38.5&#8211;162.0&#160;s), LA diagnosis (<italic toggle="yes">n</italic>&#8201;=&#8201;10, APTT: 48.5&#8211;167.5&#160;s), or anticoagulant therapy using UFH (<italic toggle="yes">n</italic>&#8201;=&#8201;10, APTT: 39.1&#8211;73.2&#160;s), VKA (<italic toggle="yes">n</italic>&#8201;=&#8201;10, APTT: 43.2&#8211;60.5&#160;s), or DOACs (<italic toggle="yes">n</italic>&#8201;=&#8201;10; 2 Dab, 3 Riv, 2 Api, and 3 Edo samples, APTT: 38.4&#8211;49.2&#160;s). APTT was measured immediately and after 2&#160;h of incubation at 37&#160;&#176;C in normal plasma (CRYOcheck Pooled Normal Plasma, Precision BioLogic Inc., Canada), APTT abnormal plasma, and their 1:1 mixture, using the same APTT reagent and analyzer used for constructing the DL model. The results of the mixing tests were interpreted using a set of numerical indexes, ALD50 and Was, as proposed by Shimomura et al.<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>, with the former used for immediate interpretation and the latter for post-incubation interpretation. The ALD50 was calculated using immediate APTT values of normal plasma, the test sample, and their 1:1 mixture, while the Was was calculated using four APTT values: the immediate and post-incubation values of both the test sample and its 1:1 mixture with normal plasma. There are various numerical indexes reported with cutoff values depending on the APTT reagents used<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR43">43</xref></sup>. We selected the ALD50 and Was indexes because they have suitable cutoff values for the APTT reagent used in this study<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. When the Was index was &#8805;&#8201;10.2%, the cause of APTT prolongation was considered to be coagulation factor inhibitors. When the Was index was &lt;&#8201;10.2% and the ALD50 index was &#8805;&#8201;87.8%, the cause was LA. When the Was index was &lt;&#8201;10.2% and the ALD50 index was &lt;&#8201;87.8%, the cause was considered to be coagulation factor deficiency.</p></sec><sec id="Sec15"><title>Statistical analysis</title><p id="Par88">The differences in AUC values were statistically analyzed using Delong&#8217;s test, implemented in the open-source package pROC (ver. 1.18.5) in R (ver. 4.5.0)<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. An alpha level of <italic toggle="yes">P</italic>&#8201;=&#8201;0.05 was used as the significance criterion.</p><p id="Par89">To evaluate the effect of introducing the adjustment method, AUC values obtained from the adjustment and non-adjustment methods were compared for each of the three CWA parameters (|min1|, |min2|, and max2) within each group (hemophilia, LA, UFH, VKA, and DOACs). Specifically, comparisons were made between |min1| and Ad|min1|, |min2| and Ad|min2|, and max2 and Ad_max2 in each group.</p><p id="Par90">To assess the effect of introducing the DL techniques, AUC values of the adjusted CWA parameters (Ad|min1|, Ad|min2|, and Ad_max2) were compared with those of the corresponding DL models developed using adjusted first- and second-derivative curves, respectively, within each group (hemophilia, LA, UFH, VKA, and DOACs). Specifically, comparisons were made between Ad|min1| and DL model using adjusted first-derivative curves, Ad|min2| and DL model using adjusted second-derivative curves, and Ad_max2 and DL model using adjusted second-derivative curves, because Ad|min1| was a portion of the adjusted first-derivative curve, and Ad|min2| and Ad_max2 were the portion of the adjusted second-derivative curve. The CWA curves used were from single-wavelength (660&#160;nm).</p><p id="Par91">To examine the effect of introducing the multi-wavelength CWA techniques, AUC values of the DL model developed using all CWA curves at single wavelength were compared with those at multiple wavelengths within each group (hemophilia, LA, UFH, VKA, and DOACs).</p></sec></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We would like to thank Editage (www.editage.com) for English language editing.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Conception and design of the study: M.Matsuda, D.S., T.S., Y.T., N.A., M.Moriyama, and T.M. Acquisition of data: M.Matsuda, D.S., T.S., Y.T., K.N., and T.M.Analysis and interpretation of data: M.Matsuda, D.S., T.S., Y.T., H.K., K.N., N.A., Y.H., M.K., M.Moriyama, and T.M. Drafting the article: M.Matsuda, D.S., T.S., Y.T., N.A., and T.M. Revising the manuscript critically for important intellectual content: M.Matsuda, D.S., H.K., K.N., N.A., Y.H., M.K., M.Moriyama, and T.M.Final approval of the version to be submitted: M.Matsuda, D.S., T.S., Y.T., H.K., K.N., N.A., Y.H., M.K., M.Moriyama, and T.M.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The authors received no specific funding for this work.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets generated during and/or analyzed during the current study are not publicly available because a patent application has been filed relating to this work but are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par92">T.S., Y.T., H.K., K.N., and N.A. are employee of Sysmex Corp., Japan. The other authors have no competing interests to declare.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lippi</surname><given-names>G</given-names></name><name name-style="western"><surname>Favaloro</surname><given-names>EJ</given-names></name></person-group><article-title>Activated partial thromboplastin time: new tricks for an old dogma</article-title><source>Semin Thromb. Hemost.</source><year>2008</year><volume>34</volume><fpage>604</fpage><lpage>611</lpage><pub-id pub-id-type="pmid">19085761</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0028-1104539</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Lippi, G. &amp; Favaloro, E. J. Activated partial thromboplastin time: new tricks for an old dogma. <italic toggle="yes">Semin Thromb. Hemost.</italic><bold>34</bold>, 604&#8211;611 (2008).<pub-id pub-id-type="pmid">19085761</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0028-1104539</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Favaloro</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Kershaw</surname><given-names>G</given-names></name><name name-style="western"><surname>Mohammed</surname><given-names>S</given-names></name><name name-style="western"><surname>Lippi</surname><given-names>G</given-names></name></person-group><article-title>How to optimize activated partial thromboplastin time (APTT) testing: solutions to Establishing and verifying normal reference intervals and assessing APTT reagents for sensitivity to heparin, lupus anticoagulant, and clotting factors</article-title><source>Semin Thromb. Hemost.</source><year>2019</year><volume>45</volume><fpage>22</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">30630206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0038-1677018</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Favaloro, E. J., Kershaw, G., Mohammed, S. &amp; Lippi, G. How to optimize activated partial thromboplastin time (APTT) testing: solutions to Establishing and verifying normal reference intervals and assessing APTT reagents for sensitivity to heparin, lupus anticoagulant, and clotting factors. <italic toggle="yes">Semin Thromb. Hemost.</italic><bold>45</bold>, 22&#8211;35 (2019).<pub-id pub-id-type="pmid">30630206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0038-1677018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zanon</surname><given-names>E</given-names></name></person-group><article-title>Acquired hemophilia A: an update on the etiopathogenesis, diagnosis, and treatment</article-title><source>Diagnostics (Basel)</source><year>2023</year><volume>13</volume><fpage>420</fpage><pub-id pub-id-type="pmid">36766524</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/diagnostics13030420</pub-id><pub-id pub-id-type="pmcid">PMC9914651</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Zanon, E. Acquired hemophilia A: an update on the etiopathogenesis, diagnosis, and treatment. <italic toggle="yes">Diagnostics (Basel)</italic>. <bold>13</bold>, 420 (2023).<pub-id pub-id-type="pmid">36766524</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/diagnostics13030420</pub-id><pub-id pub-id-type="pmcid">PMC9914651</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barbosa</surname><given-names>ACN</given-names></name><etal/></person-group><article-title>Prolonged APTT of unknown etiology: A systematic evaluation of causes and laboratory resource use in an outpatient hemostasis academic unit</article-title><source>Res. Pract. Thromb. Haemost</source><year>2019</year><volume>3</volume><fpage>749</fpage><lpage>757</lpage><pub-id pub-id-type="pmid">31624795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/rth2.12252</pub-id><pub-id pub-id-type="pmcid">PMC6782020</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Barbosa, A. C. N. et al. Prolonged APTT of unknown etiology: A systematic evaluation of causes and laboratory resource use in an outpatient hemostasis academic unit. <italic toggle="yes">Res. Pract. Thromb. Haemost</italic>. <bold>3</bold>, 749&#8211;757 (2019).<pub-id pub-id-type="pmid">31624795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/rth2.12252</pub-id><pub-id pub-id-type="pmcid">PMC6782020</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rasmussen</surname><given-names>KL</given-names></name><name name-style="western"><surname>Philips</surname><given-names>M</given-names></name><name name-style="western"><surname>Tripodi</surname><given-names>A</given-names></name><name name-style="western"><surname>Goetze</surname><given-names>JP</given-names></name></person-group><article-title>Unexpected, isolated activated partial thromboplastin time prolongation: A practical mini-review</article-title><source>Eur. J. Haematol.</source><year>2020</year><volume>104</volume><fpage>519</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">32049377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ejh.13394</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Rasmussen, K. L., Philips, M., Tripodi, A. &amp; Goetze, J. P. Unexpected, isolated activated partial thromboplastin time prolongation: A practical mini-review. <italic toggle="yes">Eur. J. Haematol.</italic><bold>104</bold>, 519&#8211;525 (2020).<pub-id pub-id-type="pmid">32049377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ejh.13394</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Favaloro</surname><given-names>EJ</given-names></name></person-group><article-title>Coagulation mixing studies: utility, algorithmic strategies and limitations for lupus anticoagulant testing or follow up of abnormal coagulation tests</article-title><source>Am. J. Hematol.</source><year>2020</year><volume>95</volume><fpage>117</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">31674066</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ajh.25669</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Favaloro, E. J. Coagulation mixing studies: utility, algorithmic strategies and limitations for lupus anticoagulant testing or follow up of abnormal coagulation tests. <italic toggle="yes">Am. J. Hematol.</italic><bold>95</bold>, 117&#8211;128 (2020).<pub-id pub-id-type="pmid">31674066</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ajh.25669</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kershaw</surname><given-names>G</given-names></name><name name-style="western"><surname>Orellana</surname><given-names>D</given-names></name></person-group><article-title>Mixing tests: diagnostic aides in the investigation of prolonged prothrombin times and activated partial thromboplastin times</article-title><source>Semin Thromb. Hemost.</source><year>2013</year><volume>39</volume><fpage>283</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">23457048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0033-1336832</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Kershaw, G. &amp; Orellana, D. Mixing tests: diagnostic aides in the investigation of prolonged prothrombin times and activated partial thromboplastin times. <italic toggle="yes">Semin Thromb. Hemost.</italic><bold>39</bold>, 283&#8211;290 (2013).<pub-id pub-id-type="pmid">23457048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0033-1336832</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cabo</surname><given-names>J</given-names></name><etal/></person-group><article-title>Variability among commercial batches of normal pooled plasma in lupus anticoagulant testing</article-title><source>Int. J. Lab. Hematol.</source><year>2023</year><volume>45</volume><fpage>126</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">36222181</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ijlh.13977</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Cabo, J. et al. Variability among commercial batches of normal pooled plasma in lupus anticoagulant testing. <italic toggle="yes">Int. J. Lab. Hematol.</italic><bold>45</bold>, 126&#8211;136 (2023).<pub-id pub-id-type="pmid">36222181</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ijlh.13977</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsuda</surname><given-names>M</given-names></name><etal/></person-group><article-title>Performance characteristics of 5 numerical indexes in mixing test interpretation under coexistence of lupus anticoagulant and coagulation factor deficiency</article-title><source>Res. Pract. Thromb. Haemost</source><year>2023</year><volume>7</volume><fpage>100065</fpage><pub-id pub-id-type="pmid">36891278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.rpth.2023.100065</pub-id><pub-id pub-id-type="pmcid">PMC9986643</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Matsuda, M. et al. Performance characteristics of 5 numerical indexes in mixing test interpretation under coexistence of lupus anticoagulant and coagulation factor deficiency. <italic toggle="yes">Res. Pract. Thromb. Haemost</italic>. <bold>7</bold>, 100065 (2023).<pub-id pub-id-type="pmid">36891278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.rpth.2023.100065</pub-id><pub-id pub-id-type="pmcid">PMC9986643</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braun</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Properties of optical data from activated partial thromboplastin time and prothrombin time assays</article-title><source>Thromb. Haemost</source><year>1997</year><volume>78</volume><fpage>1079</fpage><lpage>1087</lpage><pub-id pub-id-type="pmid">9308757</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Braun, P. J. et al. Properties of optical data from activated partial thromboplastin time and prothrombin time assays. <italic toggle="yes">Thromb. Haemost</italic>. <bold>78</bold>, 1079&#8211;1087 (1997).<pub-id pub-id-type="pmid">9308757</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shima</surname><given-names>M</given-names></name><etal/></person-group><article-title>The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C)</article-title><source>Thromb. Haemost</source><year>2002</year><volume>87</volume><fpage>436</fpage><lpage>441</lpage><pub-id pub-id-type="pmid">11916076</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Shima, M. et al. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C). <italic toggle="yes">Thromb. Haemost</italic>. <bold>87</bold>, 436&#8211;441 (2002).<pub-id pub-id-type="pmid">11916076</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shima</surname><given-names>M</given-names></name><name name-style="western"><surname>Thachil</surname><given-names>J</given-names></name><name name-style="western"><surname>Nair</surname><given-names>SC</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>A</given-names></name></person-group><article-title>Scientific and standardization committee. Towards standardization of clot waveform analysis and recommendations for its clinical applications</article-title><source>J. Thromb. Haemost</source><year>2013</year><volume>11</volume><fpage>1417</fpage><lpage>1420</lpage><pub-id pub-id-type="pmid">23648068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jth.12287</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Shima, M., Thachil, J., Nair, S. C. &amp; Srivastava, A. Scientific and standardization committee. Towards standardization of clot waveform analysis and recommendations for its clinical applications. <italic toggle="yes">J. Thromb. Haemost</italic>. <bold>11</bold>, 1417&#8211;1420 (2013).<pub-id pub-id-type="pmid">23648068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jth.12287</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsumoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Nogami</surname><given-names>K</given-names></name><name name-style="western"><surname>Shima</surname><given-names>M</given-names></name></person-group><article-title>A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity</article-title><source>Int. J. Hematol.</source><year>2017</year><volume>105</volume><fpage>174</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">27730530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12185-016-2108-x</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Matsumoto, T., Nogami, K. &amp; Shima, M. A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity. <italic toggle="yes">Int. J. Hematol.</italic><bold>105</bold>, 174&#8211;183 (2017).<pub-id pub-id-type="pmid">27730530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12185-016-2108-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sevenet</surname><given-names>PO</given-names></name><name name-style="western"><surname>Depasse</surname><given-names>F</given-names></name></person-group><article-title>Clot waveform analysis: where do we stand in 2017?</article-title><source>Int. J. Lab. Hematol.</source><year>2017</year><volume>39</volume><fpage>561</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">28876509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ijlh.12724</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Sevenet, P. O. &amp; Depasse, F. Clot waveform analysis: where do we stand in 2017? <italic toggle="yes">Int. J. Lab. Hematol.</italic><bold>39</bold>, 561&#8211;568 (2017).<pub-id pub-id-type="pmid">28876509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ijlh.12724</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wada</surname><given-names>H</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Ohishi</surname><given-names>K</given-names></name><name name-style="western"><surname>Shiraki</surname><given-names>K</given-names></name><name name-style="western"><surname>Shimaoka</surname><given-names>M</given-names></name></person-group><article-title>Update on the clot waveform analysis</article-title><source>Clin. Appl. Thromb. Hemost.</source><year>2020</year><volume>26</volume><fpage>1076029620912027</fpage><pub-id pub-id-type="pmid">32862666</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1076029620912027</pub-id><pub-id pub-id-type="pmcid">PMC7466886</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Wada, H., Matsumoto, T., Ohishi, K., Shiraki, K. &amp; Shimaoka, M. Update on the clot waveform analysis. <italic toggle="yes">Clin. Appl. Thromb. Hemost.</italic><bold>26</bold>, 1076029620912027 (2020).<pub-id pub-id-type="pmid">32862666</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1076029620912027</pub-id><pub-id pub-id-type="pmcid">PMC7466886</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solano</surname><given-names>C</given-names></name><name name-style="western"><surname>Zerafa</surname><given-names>P</given-names></name><name name-style="western"><surname>Bird</surname><given-names>R</given-names></name></person-group><article-title>A study of atypical APTT derivative curves on the ACL TOP coagulation analyser</article-title><source>Int. J. Lab. Hematol.</source><year>2011</year><volume>33</volume><fpage>67</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">20649909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1751-553X.2010.01248.x</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Solano, C., Zerafa, P. &amp; Bird, R. A study of atypical APTT derivative curves on the ACL TOP coagulation analyser. <italic toggle="yes">Int. J. Lab. Hematol.</italic><bold>33</bold>, 67&#8211;78 (2011).<pub-id pub-id-type="pmid">20649909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1751-553X.2010.01248.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tokunaga</surname><given-names>N</given-names></name><etal/></person-group><article-title>Usefulness of the second-derivative curve of activated partial thromboplastin time on the ACL-TOP coagulation analyzer for detecting factor deficiencies</article-title><source>Blood Coagul Fibrinolysis</source><year>2016</year><volume>27</volume><fpage>474</fpage><lpage>476</lpage><pub-id pub-id-type="pmid">26523912</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MBC.0000000000000436</pub-id><pub-id pub-id-type="pmcid">PMC4888921</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Tokunaga, N. et al. Usefulness of the second-derivative curve of activated partial thromboplastin time on the ACL-TOP coagulation analyzer for detecting factor deficiencies. <italic toggle="yes">Blood Coagul Fibrinolysis</italic>. <bold>27</bold>, 474&#8211;476 (2016).<pub-id pub-id-type="pmid">26523912</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MBC.0000000000000436</pub-id><pub-id pub-id-type="pmcid">PMC4888921</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimomura</surname><given-names>D</given-names></name><etal/></person-group><article-title>The first-derivative curve of the coagulation waveform reveals the cause of aPTT prolongation</article-title><source>Clin. Appl. Thromb. Hemost.</source><year>2020</year><volume>26</volume><fpage>1076029620978810</fpage><pub-id pub-id-type="pmid">33372824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1076029620978810</pub-id><pub-id pub-id-type="pmcid">PMC7783875</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Shimomura, D. et al. The first-derivative curve of the coagulation waveform reveals the cause of aPTT prolongation. <italic toggle="yes">Clin. Appl. Thromb. Hemost.</italic><bold>26</bold>, 1076029620978810 (2020).<pub-id pub-id-type="pmid">33372824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1076029620978810</pub-id><pub-id pub-id-type="pmcid">PMC7783875</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nogami</surname><given-names>K</given-names></name><etal/></person-group><article-title>Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor ixa/factor X bispecific antibody Emicizumab</article-title><source>J. Thromb. Haemost</source><year>2018</year><volume>16</volume><fpage>1078</fpage><lpage>1088</lpage><pub-id pub-id-type="pmid">29645406</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jth.14022</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Nogami, K. et al. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor ixa/factor X bispecific antibody Emicizumab. <italic toggle="yes">J. Thromb. Haemost</italic>. <bold>16</bold>, 1078&#8211;1088 (2018).<pub-id pub-id-type="pmid">29645406</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jth.14022</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wakui</surname><given-names>M</given-names></name><etal/></person-group><article-title>Comparison of clot waveform analysis with or without adjustment between prothrombin time and activated partial thromboplastin time assays to assess in vitro effects of direct oral anticoagulants</article-title><source>Clin. Chim. Acta</source><year>2024</year><volume>562</volume><fpage>119887</fpage><pub-id pub-id-type="pmid">39059480</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cca.2024.119887</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Wakui, M. et al. Comparison of clot waveform analysis with or without adjustment between prothrombin time and activated partial thromboplastin time assays to assess in vitro effects of direct oral anticoagulants. <italic toggle="yes">Clin. Chim. Acta</italic>. <bold>562</bold>, 119887 (2024).<pub-id pub-id-type="pmid">39059480</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cca.2024.119887</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evrard</surname><given-names>J</given-names></name><etal/></person-group><article-title>Optimal wavelength for the clot waveform analysis: determination of the best resolution with minimal interference of the reagents</article-title><source>Int. J. Lab. Hematol.</source><year>2019</year><volume>41</volume><fpage>316</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">30730600</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ijlh.12975</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Evrard, J. et al. Optimal wavelength for the clot waveform analysis: determination of the best resolution with minimal interference of the reagents. <italic toggle="yes">Int. J. Lab. Hematol.</italic><bold>41</bold>, 316&#8211;324 (2019).<pub-id pub-id-type="pmid">30730600</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ijlh.12975</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Givens</surname><given-names>TB</given-names></name><name name-style="western"><surname>Braun</surname><given-names>PJ</given-names></name></person-group><article-title>Classification of factor deficiencies from coagulation assays using neural networks</article-title><source>Int. J. Med. Inf.</source><year>1997</year><volume>46</volume><fpage>129</fpage><lpage>143</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1386-5056(97)00065-8</pub-id><pub-id pub-id-type="pmid">9373776</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Givens, T. B. &amp; Braun, P. J. Classification of factor deficiencies from coagulation assays using neural networks. <italic toggle="yes">Int. J. Med. Inf.</italic><bold>46</bold>, 129&#8211;143 (1997).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1386-5056(97)00065-8</pub-id><pub-id pub-id-type="pmid">9373776</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanouchi</surname><given-names>K</given-names></name><name name-style="western"><surname>Narimatsu</surname><given-names>H</given-names></name><name name-style="western"><surname>Shirata</surname><given-names>T</given-names></name><name name-style="western"><surname>Morikane</surname><given-names>K</given-names></name></person-group><article-title>Diagnostic analysis of lupus anticoagulant using clot waveform analysis in activated partial thromboplastin time prolonged cases: A retrospective analysis</article-title><source>Health Sci. Rep.</source><year>2021</year><volume>4</volume><fpage>e258</fpage><pub-id pub-id-type="pmid">33738342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hsr2.258</pub-id><pub-id pub-id-type="pmcid">PMC7953360</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Kanouchi, K., Narimatsu, H., Shirata, T. &amp; Morikane, K. Diagnostic analysis of lupus anticoagulant using clot waveform analysis in activated partial thromboplastin time prolonged cases: A retrospective analysis. <italic toggle="yes">Health Sci. Rep.</italic><bold>4</bold>, e258 (2021).<pub-id pub-id-type="pmid">33738342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hsr2.258</pub-id><pub-id pub-id-type="pmcid">PMC7953360</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wakui</surname><given-names>M</given-names></name><etal/></person-group><article-title>Assessment of in vitro effects of direct thrombin inhibitors and activated factor X inhibitors through clot waveform analysis</article-title><source>J. Clin. Pathol.</source><year>2019</year><volume>72</volume><fpage>244</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">30518630</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jclinpath-2018-205517</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Wakui, M. et al. Assessment of in vitro effects of direct thrombin inhibitors and activated factor X inhibitors through clot waveform analysis. <italic toggle="yes">J. Clin. Pathol.</italic><bold>72</bold>, 244&#8211;250 (2019).<pub-id pub-id-type="pmid">30518630</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jclinpath-2018-205517</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wakui</surname><given-names>M</given-names></name><etal/></person-group><article-title>Characterisation of antithrombin-dependent anticoagulants through clot waveform analysis to potentially distinguish them from antithrombin-independent inhibitors targeting activated coagulation factors</article-title><source>J. Clin. Pathol.</source><year>2021</year><volume>74</volume><fpage>251</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">32796051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jclinpath-2020-206835</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Wakui, M. et al. Characterisation of antithrombin-dependent anticoagulants through clot waveform analysis to potentially distinguish them from antithrombin-independent inhibitors targeting activated coagulation factors. <italic toggle="yes">J. Clin. Pathol.</italic><bold>74</bold>, 251&#8211;256 (2021).<pub-id pub-id-type="pmid">32796051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jclinpath-2020-206835</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsuda</surname><given-names>M</given-names></name><name name-style="western"><surname>Morita</surname><given-names>Y</given-names></name><name name-style="western"><surname>Moriyama</surname><given-names>M</given-names></name><name name-style="western"><surname>Hoshiyama</surname><given-names>Y</given-names></name><name name-style="western"><surname>Narita</surname><given-names>I</given-names></name></person-group><article-title>Establishment of activated partial thromboplastin time reference intervals and their clinical utility, using three reagents</article-title><source>Clin. Lab. Sci. J.</source><year>2021</year><volume>46</volume><fpage>537</fpage><lpage>549</lpage></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Matsuda, M., Morita, Y., Moriyama, M., Hoshiyama, Y. &amp; Narita, I. Establishment of activated partial thromboplastin time reference intervals and their clinical utility, using three reagents. <italic toggle="yes">Clin. Lab. Sci. J.</italic><bold>46</bold>, 537&#8211;549 (2021).</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>WH</given-names></name><etal/></person-group><article-title>Reagent effects on the activated partial thromboplastin time clot waveform analysis: A multi-centre study</article-title><source>Diagnostics (Basel)</source><year>2023</year><volume>13</volume><fpage>2447</fpage><pub-id pub-id-type="pmid">37510191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/diagnostics13142447</pub-id><pub-id pub-id-type="pmcid">PMC10377778</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Wong, W. H. et al. Reagent effects on the activated partial thromboplastin time clot waveform analysis: A multi-centre study. <italic toggle="yes">Diagnostics (Basel)</italic>. <bold>13</bold>, 2447 (2023).<pub-id pub-id-type="pmid">37510191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/diagnostics13142447</pub-id><pub-id pub-id-type="pmcid">PMC10377778</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ieko</surname><given-names>M</given-names></name><etal/></person-group><article-title>Expert consensus regarding standardization of sample Preparation for clotting time assays</article-title><source>Int. J. Hematol.</source><year>2020</year><volume>112</volume><fpage>614</fpage><lpage>620</lpage><pub-id pub-id-type="pmid">32929688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12185-020-02983-x</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Ieko, M. et al. Expert consensus regarding standardization of sample Preparation for clotting time assays. <italic toggle="yes">Int. J. Hematol.</italic><bold>112</bold>, 614&#8211;620 (2020).<pub-id pub-id-type="pmid">32929688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12185-020-02983-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Deep learning for visual understanding: A review</article-title><source>Neurocomputing</source><year>2016</year><volume>187</volume><fpage>27</fpage><lpage>48</lpage></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Guo, Y. et al. Deep learning for visual understanding: A review. <italic toggle="yes">Neurocomputing</italic><bold>187</bold>, 27&#8211;48 (2016).</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>A</given-names></name><name name-style="western"><surname>Sohail</surname><given-names>A</given-names></name><name name-style="western"><surname>Zahoora</surname><given-names>U</given-names></name><name name-style="western"><surname>Qureshi</surname><given-names>AS</given-names></name></person-group><article-title>A survey of the recent architectures of deep convolutional neural networks</article-title><source>Artif. Intell. Rev.</source><year>2020</year><volume>53</volume><fpage>5455</fpage><lpage>5516</lpage></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Khan, A., Sohail, A., Zahoora, U. &amp; Qureshi, A. S. A survey of the recent architectures of deep convolutional neural networks. <italic toggle="yes">Artif. Intell. Rev.</italic><bold>53</bold>, 5455&#8211;5516 (2020).</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhatt</surname><given-names>D</given-names></name><etal/></person-group><article-title>CNN variants for computer vision: history, architecture, application, challenges and future scope</article-title><source>Electronics</source><year>2021</year><volume>10</volume><fpage>2470</fpage></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Bhatt, D. et al. CNN variants for computer vision: history, architecture, application, challenges and future scope. <italic toggle="yes">Electronics</italic><bold>10</bold>, 2470 (2021).</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Litjens</surname><given-names>G</given-names></name><etal/></person-group><article-title>A survey on deep learning in medical image analysis</article-title><source>Med. Image Anal.</source><year>2017</year><volume>42</volume><fpage>60</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">28778026</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.media.2017.07.005</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Litjens, G. et al. A survey on deep learning in medical image analysis. <italic toggle="yes">Med. Image Anal.</italic><bold>42</bold>, 60&#8211;88 (2017).<pub-id pub-id-type="pmid">28778026</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.media.2017.07.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>HP</given-names></name><name name-style="western"><surname>Samala</surname><given-names>RK</given-names></name><name name-style="western"><surname>Hadjiiski</surname><given-names>LM</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>C</given-names></name></person-group><article-title>Deep learning in medical image analysis</article-title><source>Adv. Exp. Med. Biol.</source><year>2020</year><volume>1213</volume><fpage>3</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">32030660</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-030-33128-3_1</pub-id><pub-id pub-id-type="pmcid">PMC7442218</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Chan, H. P., Samala, R. K., Hadjiiski, L. M. &amp; Zhou, C. Deep learning in medical image analysis. <italic toggle="yes">Adv. Exp. Med. Biol.</italic><bold>1213</bold>, 3&#8211;21 (2020).<pub-id pub-id-type="pmid">32030660</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-030-33128-3_1</pub-id><pub-id pub-id-type="pmcid">PMC7442218</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Recent advances and clinical applications of deep learning in medical image analysis</article-title><source>Med. Image Anal.</source><year>2022</year><volume>79</volume><fpage>102444</fpage><pub-id pub-id-type="pmid">35472844</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.media.2022.102444</pub-id><pub-id pub-id-type="pmcid">PMC9156578</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Chen, X. et al. Recent advances and clinical applications of deep learning in medical image analysis. <italic toggle="yes">Med. Image Anal.</italic><bold>79</bold>, 102444 (2022).<pub-id pub-id-type="pmid">35472844</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.media.2022.102444</pub-id><pub-id pub-id-type="pmcid">PMC9156578</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munir</surname><given-names>K</given-names></name><name name-style="western"><surname>Elahi</surname><given-names>H</given-names></name><name name-style="western"><surname>Ayub</surname><given-names>A</given-names></name><name name-style="western"><surname>Frezza</surname><given-names>F</given-names></name><name name-style="western"><surname>Rizzi</surname><given-names>A</given-names></name></person-group><article-title>Cancer diagnosis using deep learning: A bibliographic review</article-title><source>Cancers</source><year>2019</year><volume>11</volume><fpage>1235</fpage><pub-id pub-id-type="pmid">31450799</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers11091235</pub-id><pub-id pub-id-type="pmcid">PMC6770116</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Munir, K., Elahi, H., Ayub, A., Frezza, F. &amp; Rizzi, A. Cancer diagnosis using deep learning: A bibliographic review. <italic toggle="yes">Cancers</italic><bold>11</bold>, 1235 (2019).<pub-id pub-id-type="pmid">31450799</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers11091235</pub-id><pub-id pub-id-type="pmcid">PMC6770116</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Badrigilan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Deep learning approaches for automated classification and segmentation of head and neck cancers and brain tumors in magnetic resonance images: a meta-analysis study</article-title><source>Int. J. Comput. Assist. Radiol. Surg.</source><year>2021</year><volume>16</volume><fpage>529</fpage><lpage>542</lpage><pub-id pub-id-type="pmid">33666859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11548-021-02326-z</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Badrigilan, S. et al. Deep learning approaches for automated classification and segmentation of head and neck cancers and brain tumors in magnetic resonance images: a meta-analysis study. <italic toggle="yes">Int. J. Comput. Assist. Radiol. Surg.</italic><bold>16</bold>, 529&#8211;542 (2021).<pub-id pub-id-type="pmid">33666859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11548-021-02326-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alhasan</surname><given-names>AS</given-names></name></person-group><article-title>Clinical applications of artificial intelligence, machine learning, and deep learning in the imaging of gliomas: A systematic review</article-title><source>Cureus</source><year>2021</year><volume>13</volume><fpage>e19580</fpage><pub-id pub-id-type="pmid">34926051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.19580</pub-id><pub-id pub-id-type="pmcid">PMC8671075</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Alhasan, A. S. Clinical applications of artificial intelligence, machine learning, and deep learning in the imaging of gliomas: A systematic review. <italic toggle="yes">Cureus</italic><bold>13</bold>, e19580 (2021).<pub-id pub-id-type="pmid">34926051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.19580</pub-id><pub-id pub-id-type="pmcid">PMC8671075</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">Abadi, M. et al. TensorFlow: Large-scale machine learning on heterogeneous distributed systems. <italic toggle="yes">Preprint arXiv</italic> (2016). <ext-link ext-link-type="uri" xlink:href="https://arxiv.org/abs/1603.04467">https://arxiv.org/abs/1603.04467</ext-link></mixed-citation></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rampasek</surname><given-names>L</given-names></name><name name-style="western"><surname>Goldenberg</surname><given-names>A</given-names></name><name name-style="western"><surname>TensorFlow</surname></name></person-group><article-title>Biology&#8217;s gateway to deep learning?</article-title><source>Cell. Syst.</source><year>2016</year><volume>2</volume><fpage>12</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">27136685</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cels.2016.01.009</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Rampasek, L., Goldenberg, A. &amp; TensorFlow Biology&#8217;s gateway to deep learning? <italic toggle="yes">Cell. Syst.</italic><bold>2</bold>, 12&#8211;14 (2016).<pub-id pub-id-type="pmid">27136685</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cels.2016.01.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akobeng</surname><given-names>AK</given-names></name></person-group><article-title>Understanding diagnostic tests 3: receiver operating characteristic curves</article-title><source>Acta Paediatr.</source><year>2007</year><volume>96</volume><fpage>644</fpage><lpage>647</lpage><pub-id pub-id-type="pmid">17376185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1651-2227.2006.00178.x</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Akobeng, A. K. Understanding diagnostic tests 3: receiver operating characteristic curves. <italic toggle="yes">Acta Paediatr.</italic><bold>96</bold>, 644&#8211;647 (2007).<pub-id pub-id-type="pmid">17376185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1651-2227.2006.00178.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pedregosa</surname><given-names>F</given-names></name><etal/></person-group><article-title>Scikit-learn: machine learning in python</article-title><source>J. Mach. Learn. Res.</source><year>2011</year><volume>12</volume><fpage>2825</fpage><lpage>2830</lpage></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Pedregosa, F. et al. Scikit-learn: machine learning in python. <italic toggle="yes">J. Mach. Learn. Res.</italic><bold>12</bold>, 2825&#8211;2830 (2011).</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimomura</surname><given-names>D</given-names></name><etal/></person-group><article-title>New method to differentiate between lupus anticoagulants, progressive coagulation inhibitors and coagulation factor deficiencies in the mixing tests</article-title><source>Int. J. Lab. Hematol.</source><year>2024</year><volume>46</volume><fpage>1084</fpage><lpage>1091</lpage><pub-id pub-id-type="pmid">38644054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ijlh.14289</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Shimomura, D. et al. New method to differentiate between lupus anticoagulants, progressive coagulation inhibitors and coagulation factor deficiencies in the mixing tests. <italic toggle="yes">Int. J. Lab. Hematol.</italic><bold>46</bold>, 1084&#8211;1091 (2024).<pub-id pub-id-type="pmid">38644054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ijlh.14289</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumano</surname><given-names>O</given-names></name><name name-style="western"><surname>Moore</surname><given-names>GW</given-names></name></person-group><article-title>Lupus anticoagulant mixing tests for multiple reagents are more sensitive if interpreted with a mixing test-specific cut-off than index of Circulating anticoagulant</article-title><source>Res. Pract. Thromb. Haemost</source><year>2017</year><volume>2</volume><fpage>105</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">30046711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/rth2.12069</pub-id><pub-id pub-id-type="pmcid">PMC6055558</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Kumano, O. &amp; Moore, G. W. Lupus anticoagulant mixing tests for multiple reagents are more sensitive if interpreted with a mixing test-specific cut-off than index of Circulating anticoagulant. <italic toggle="yes">Res. Pract. Thromb. Haemost</italic>. <bold>2</bold>, 105&#8211;113 (2017).<pub-id pub-id-type="pmid">30046711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/rth2.12069</pub-id><pub-id pub-id-type="pmcid">PMC6055558</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robin</surname><given-names>X</given-names></name><etal/></person-group><article-title>pROC: an open-source package for R and S&#8201;+&#8201;to analyze and compare ROC curves</article-title><source>BMC Bioinform.</source><year>2011</year><volume>12</volume><fpage>77</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2105-12-77</pub-id><pub-id pub-id-type="pmcid">PMC3068975</pub-id><pub-id pub-id-type="pmid">21414208</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Robin, X. et al. pROC: an open-source package for R and S&#8201;+&#8201;to analyze and compare ROC curves. <italic toggle="yes">BMC Bioinform.</italic><bold>12</bold>, 77 (2011).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2105-12-77</pub-id><pub-id pub-id-type="pmcid">PMC3068975</pub-id><pub-id pub-id-type="pmid">21414208</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>